Next Article in Journal
Development of the Breastfed Infant Oral Microbiome Is Associated with Concentrations and Intakes of Human Milk Oligosaccharides
Previous Article in Journal
Design and Validation of the Index of Adherence to the Dietary Guidelines for Chile 2022 (GABAS-Index 17)
error_outline You can access the new MDPI.com website here. Explore and share your feedback with us.
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 17
Issue 22
10.3390/nu17223619
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

A Systematic Review of Palmitate-Mediated Insulin Resistance in C2C12 Myotubes

by
John M. Zimmerman
,
Alexa J. Klein
,
Kipton B. Travis
and
Roger A. Vaughan
*
Department of Health and Human Performance, High Point University, High Point, NC 27268, USA
*
Author to whom correspondence should be addressed.
Nutrients 2025, 17(22), 3619; https://doi.org/10.3390/nu17223619
Submission received: 12 August 2025 / Revised: 23 October 2025 / Accepted: 14 November 2025 / Published: 20 November 2025
(This article belongs to the Section Nutrition and Diabetes)
Browse Figures
Versions Notes

Abstract

Background/Objectives: Skeletal muscle plays a pivotal role in whole-body glucose metabolism and is a major target in the pathogenesis and treatment of insulin resistance and type 2 diabetes. The C2C12 myotube cell line is one of the most used in vitro models to investigate mechanisms of insulin resistance. This systematic review (1) summarizes the most common experimental conditions including palmitate concentrations and treatment durations used to induce insulin resistance in C2C12 myotubes; (2) characterizes outcomes related to insulin resistance; and (3) discusses strengths and limitations associated with this model. Methods: A systematic search of PubMed and Scopus was conducted using terms “C2C12 AND palmitate AND insulin resistance” and related variations. A total of 191 articles met inclusion criteria. Results: The most frequently used palmitate concentrations were 0.25 mM, 0.5 mM, and 0.75 mM for at least 16 h, which consistently led to decreased insulin-stimulated pAkt expression, GLUT4 abundance, and insulin-stimulated glucose uptake. Conclusions: The high volume and consistency of primary findings is a key strength of this article which demonstrated reduced insulin signaling across various culture conditions, treatment durations, and insulin co-stimulation protocols.

1. Introduction

Skeletal muscle is a metabolically important and active contributor to human movement and physiology. Skeletal muscle is also a consequential tissue for several pathologies such as insulin resistance and diabetes, due to its key role in glucose metabolism. For this reason, skeletal muscle is a primary target tissue for improving insulin sensitivity for the benefit of metabolic disease. Thus, exploring the mechanisms of insulin resistance in skeletal muscle is noble and offers the possibility of treatments. Among the most common experimental proof-of-concept strategies is the use of in vitro systems such as the myoblast cell culture line, C2C12. Originally, C2C12 cells were isolated from mouse skeletal muscle and can differentiate into multinucleated myotubes. Moreover, it is known to be insulin-responsive and is recognized as a convenient and effective model for studying several attributes of muscle physiology during health and disease including insulin resistance [1].
While there are other methods of inducing insulin resistance in vitro, treatment of cultured myotubes with the saturated fatty acid, specifically palmitate, is among the most widely used. A prodigious number of primary research articles have utilized this technique for inducing insulin resistance, and many of these manuscripts have focused on methods of restoring the palmitate-mediated reduction in insulin signaling. Given the widespread use of palmitate-treated myotubes as a model of insulin resistance, and because of how common the palmitate-treated C2C12 myotube model has become, there is a need to summarize the common features of this model. Therefore, this systematic review was undertaken to provide a summary of common features of palmitate-mediated insulin resistance in C2C12 myotubes.

1.1. Mechanistic Overview of Palmitate-Mediated Insulin Resistance

In general, several mechanisms have been proposed for how palmitate promotes insulin resistance, much of which has been described elsewhere [2,3]. Briefly, the accumulation of various lipid subtypes in skeletal muscle may disrupt several signaling cascades; observations which date back to 1999 [4]. For example, increased lipid accumulation including ceramides, diacylglycerols, and other lipids can activate inflammatory signaling such as I kappa B kinase (Iκκ) (directly by lipid excess or via increased protein kinase c (PKC)). PKC and Iκκ activation can ultimately inhibit insulin receptor substrate 1 (IRS1), thereby reducing cell responsiveness to insulin stimulation. Reduced IRS1 response to insulin stimulation results in reductions in Akt activation, glucose transporter 4 (GLUT4) abundance, and GLUT4 translocation to the cell membrane. Additionally, lipid toxicity is also associated with increased reactive oxygen species production, which is associated with organelle dysfunction, especially mitochondrial dysfunction. Collectively, reduced response within the canonical insulin signaling pathway, reduced mitochondrial function, and heightened reactive oxygen species (ROS) are all common features of palmitate-mediated insulin resistance in C2C12 myotubes (Figure 1). Detailed mechanistic overviews of lipid mediated insulin resistance are available at the following reviews [2,3].

1.2. Aims and Scope of Review

Given the increasing prevalence of insulin resistance and diabetes, experiments that assess basic attributes and mechanisms for potential therapeutics are important. Because palmitate-mediated insulin resistance in C2C12 myotubes is a commonly used model for assessing insulin resistance, this work aims to (1) highlight the concentrations and durations commonly used in palmitate-mediated insulin resistance in C2C12 myotubes; (2) describe the effects of palmitate-mediated insulin resistance in C2C12 myotubes on various outcomes associated with both basal and insulin signaling response; and (3) discuss the current obstacles and considerations associated with this model. In general, the most frequently used palmitate concentrations were 0.25 mM, 0.5 mM, and 0.75 mM for at least 16 h, which consistently led to decreased insulin-stimulated pAkt expression, GLUT4 abundance, and insulin-stimulated glucose uptake. Obstacles such as highly variable culture conditions, insulin stimulation protocol, use of far beyond pharmacokinetically attainable levels of palmitate and loss of cell viability are among the most prominent obstacles in the use of palmitate-treated C2C12 myotubes as a model for skeletal muscle insulin resistance. Importantly, multiple other in vitro models and cell lines are also commonly used but not included (such as L6 or Primary Human Skeletal Muscle Cells (HSkMC)). However, C2C12 myotubes were focused on in the present report because it is among the most used model of mimicking skeletal muscle in vitro.

2. Materials and Methods

2.1. General Article Search Procedure and Eligibility Criteria

Primary literature was identified by RAV first by searching PubMed and Scopus using individual “C2C12 AND palmitate AND insulin resistance”. The search was then repeated with “palmitate” substituted with “palmitic acid” both with the addition of each targeted outcome (for example “pAkt”) both with and without the presence of “insulin resistance”. Initially, full texts for each article were screened by RAV (as the abstract is insufficient in many cases to know if eligible experiments were contained within the manuscript). Articles were included and summarized if (1) C2C12 myotubes were used as the cell culture model of insulin resistance, (2) the article included a palmitate-only group along with appropriate vehicle or true control, (3) the article assessed at least one of the related outcomes associated with the canonical insulin signaling pathway of importance to the scope of the review (per PRISMA guidelines, the outcomes are included as column topics within each table). Additionally, when appropriate, experiments with modified C2C12 cell line (i.e., reporter, siRNA, etc.) were included if relevant comparisons and outcomes were included with corresponding control.

2.2. Secondary Article Screening and Inclusion Procedure

All references were initially screened for eligibility by a single reviewer (RAV) with curation completed using the publication date of 19 June 2025 (and final article curation completed as of 8 October 2025). Articles which were initially excluded were then reassessed for eligibility criteria by a second independent author (JMZ), and incorrectly omitted articles were also included and summarized. Articles that were deemed eligible following initial screening were then re-evaluated by a second independent member of the research team (JMZ, AJK, and KBT), at which point measurements/estimates of effects for each outcome were made. Estimates of outcomes were generated using ratio-metric measurements of palmitate treatment versus relevant control (or raw data was reported when available). Importantly, although quality control and risk of bias is essential to guarantee the scientific quality of each individual study, standards of reporting for in vitro experiments have changed substantially since the introduction of the model. Moreover, limited risk-of-bias assessment tools are validated for in vitro studies (specifically related to the presented outcomes), therefore a bias assessment was not performed for each report.
Additionally, because the concentrations of palmitate used in the literature varied widely (from 0.05–1.2 mM), we stratified the results from each included paper into 3 tiers of concentrations. These tiers are (1) those that used pharmacokinetically attainable levels which include concentrations ≤0.25 mM, (2) those that used palmitate concentrations that moderately exceed pharmacokinetically attainable levels ranging from 0.251–0.5 mM, and (3) those which well-exceed pharmacokinetic levels (proof-of-concept), which include treatment conditions >0.5 mM palmitate. The determination of pharmacokinetically attainable concentrations was based on observations showing levels of palmitate approximate 0.007–0.015 mM (fasting [5]) up to 0.145–0.210 mM (post-prandial [6]). Additionally, to provide a summary of the most relevant treatment conditions, a general estimate of the effect of the most common concentration and treatment duration was summarized in text for each outcome as the average relative values of palmitate treatments versus control (control = 100) following variable insulin stimulation conditions (presented as total experimental average ± SD versus relative control). Importantly, these estimated average effects do not include data for protein expression only quantified by visual confirmation (VC). Additionally, within some individual studies, multiple distinct experiments were conducted involving differing treatment conditions (such as varying treatment duration) and are therefore provided as independent rows within each Table.

3. Results

3.1. Search Results

An initial historical search identified an article published as early as 1999 which first assessed the effect of palmitate conjugated with BSA on insulin signaling in C2C12 cells [4]. Initial search results from both PubMed and Scopus identified 1325 search results. After removing duplicate articles from overlapping search results, a total of 310 articles were identified and twice-screened (initially by RAV and secondarily by a separate independent author for verification of inclusion criteria and generation of estimated effect). After further removal of articles without relevant experimental conditions and/or outcomes, unavailable texts, review articles, articles not in English, and retractions, a total of 191 articles were included (Figure 2). Further details regarding article inclusion/exclusion results (Supplementary Table S1) and raw data estimates (Supplementary File S1) are provided within the Supplemental Materials.

3.2. Organization of Data

We examined the effect of palmitate at various concentrations on insulin signaling in C2C12 myotubes, analyzing changes in phosphorylated IRS (pIRS), phosphorylated Akt (pAkt), GLUT4, and glucose uptake under both basal and insulin-stimulated states. As noted above, under normal conditions, insulin binds to its receptor and activates IRS via phosphorylation. Downstream, this activates Akt through phosphorylation, which promotes GLUT4 translocation to the cell membrane to ultimately promote glucose uptake. Therefore, to reveal the effect of palmitate on insulin signaling, we highlight the response of myotubes following insulin stimulation, which reveals the effect on responsiveness to insulin. Though, for reference and completeness, we also include the results from basal experiments within each Table. Also as noted above, because the concentrations of palmitate used in the literature varied widely (from 0.05–1.2 mM), we have stratified the results into 3 tiers of concentrations including those that approximate pharmacokinetically attainable levels which include concentrations ≤0.25 mM (Table 1). These concentrations were chosen based on observations demonstrating levels of palmitate approximate 0.007–0.015 mM (fasting [5]) up to 0.145–0.210 mM (post-prandial [6]). Additionally, other experiments were stratified as those that used palmitate concentrations that moderately exceed pharmacokinetically attainable levels ranging from 0.251–0.5 mM (Table 2), and those which well-exceeded pharmacokinetic (proof-of-concept) levels including treatment conditions >0.5 mM (Table 3). Moreover, to provide a summary of the most relevant treatment conditions, a general estimate of the effect of the most common concentration and treatment duration was summarized in text for each outcome as the average relative values of palmitate treatments versus control (control = 100%) following variable insulin stimulation conditions (presented as average ± SD). Importantly, these estimated average effects do not include data for protein expression only quantified by VC.

3.3. Effect of Pharmacokinetically Attainable Levels of Palmitate on Insulin Signaling

We began by assessing the reported effects of pharmacokinetically attainable palmitate levels (concentrations ≤ 0.25 mM), which accounted for about 1/3 of the experimental observations, on common indicators of insulin sensitivity. Expression of pAkt following insulin stimulation was the most common measurement of the inclusion criteria outcomes. Within the experiments that utilized pharmacokinetically attainable levels, 0.2 mM for 24 h was the most common set of treatment conditions. Cells treated with 0.2 mM for 24 h exhibited decreased pIRS expression (total experimental average 37.9 ± 17.0% versus control following variable insulin stimulation). Similar reductions in pAkt expression, GLUT4, and glucose uptake were observed following treatment with 0.2 mM for 24 h (total experimental average for pAkt (43.1 ± 23.2%), GLUT4 (70.0 ± 19.9%), and glucose uptake (56.0 ± 19.3%), following variable insulin stimulation conditions). Additional experimental results for all included articles that utilized treatments with pharmacokinetically attainable levels of palmitate are included in Table 1.

3.4. Effect of Moderately Higher than Pharmacokinetically Attainable Levels of Palmitate on Insulin Signaling

Next, we continued summarizing the effect of palmitate on insulin sensitivity by assessing the reported effect of experiments that utilized moderately higher than pharmacokinetically attainable levels (concentrations 0.251–0.5 mM), which, again accounted for about 1/3 of the experimental observations. Consistent with findings from Table 1, expression of pAkt following insulin stimulation was again the most common measurement of the inclusion criteria outcomes. Within the experiments that utilized moderately higher than pharmacokinetically attainable levels, 0.5 mM for 16 h was the most common set of treatment conditions. Following treatment with 0.5 mM for 16 h, the palmitate-treated cells exhibited mixed effects on pIRS expression (total experimental average 136.4 ± 69.0% versus control following variable insulin stimulation). However, like pharmacokinetically attainable levels of palmitate, 0.5 mM palmitate consistently reduced pAkt expression (57.6 ± 21.5%), GLUT4 (48.0 ± 22.2%), and glucose uptake (61.5 ± 23.8%), following variable insulin stimulation conditions. Additional experimental results for all included articles that utilized treatments with moderately higher than pharmacokinetically attainable levels of palmitate are included in Table 2.

3.5. Effect of “Proof-of-Concept” Levels of Palmitate on Insulin Signaling

Lastly, we completed summarizing the effect of palmitate on insulin sensitivity by assessing the reported effect of experiments that utilized concentrations of palmitate that are far higher than pharmacokinetically attainable levels or “proof-of-concept” levels (concentrations > 0.5 mM), which accounted for roughly the final 1/3 of the experimental observations. Once again, expression of pAkt following insulin stimulation remained the most observed measurement of the inclusion criteria outcomes. Within the experiments that utilized proof-of-concept levels, 0.75 mM for 16 h was the most common set of treatment conditions. Unlike moderately high levels of palmitate, treatment with 0.75 mM palmitate for 16 h displayed relatively consistent reductions in pIRS expression (total experimental average 68.9 ± 71.8% versus control following variable insulin stimulation). Moreover, treatment with 0.75 mM palmitate for 16 h also consistently reduced pAkt expression (50.1 ± 14.6%), GLUT4 (55.3 ± 39.6%), and glucose uptake (61.0 ± 24.7%), following variable insulin stimulation conditions. Additional experimental results for all included articles that utilized proof-of-concept levels of palmitate treatments are described in Table 3.

4. Discussion

The present systematic review examined 191 published studies that investigated palmitate-induced insulin resistance in C2C12 myotubes. In general, the most frequently used palmitate concentrations were 0.25 mM, 0.5 mM, and 0.75 mM for at least 16 h, which consistently led to decreased insulin-stimulated pAkt expression, GLUT4 abundance, and insulin-stimulated glucose uptake. Within this review, we placed an emphasis on the most common treatment conditions for each level of palmitate treatment used within experiments. Collectively, the results from the studies reveal well-conserved effects of palmitate exposure on insulin signaling and glucose uptake.

4.1. IRS

IRS activation following insulin stimulation is considered a component of the proximal canonical insulin signaling pathway [197]. The most inconsistent finding of our review was the effect of palmitate treatment on IRS activation following insulin stimulation. Of the most common treatment conditions at pharmacokinetically attainable palmitate levels, pIRS expression was consistently reduced. Conversely, experiments that utilized moderately higher than pharmacokinetically attainable palmitate levels exhibited mixed results. However, proof-of-concept concentrations which far exceed the pharmacokinetically attainable palmitate levels of palmitate found reduced IRS activation following insulin stimulation. Such disparities may be due to a concentration-dependent effect during which, at low levels, palmitate impedes the action of insulin signaling in the mechanism outlined in Figure 1. However, at levels moderately higher than those which are pharmacokinetically attainable, palmitate may activate IRS via mTORC-dependent mechanisms which can further reduce insulin sensitivity [78]. Finally, at proof-of-concept concentrations, palmitate again reduces the activation of IRS possibly due to off-target mechanisms (such as reduced cell viability, discussed below). Thus, additional dose-dependent studies should investigate the importance of timing and concentration of palmitate treatment to elucidate if the disparate findings across concentrations are due to experimental variability, or the speculated hypothesis outlined above involving both concentration-dependent effects confounded by cytotoxicity.

4.2. Akt

Unlike IRS, Akt activation following insulin stimulation was the most common measurement and most consistent finding in the present review. In fact, consistently reduced pAkt expression following insulin stimulation was observed across all levels of palmitate treatment. That said, like IRS, Akt activation is considered a component of the proximal canonical insulin signaling pathway. As such, it has been discussed that under some experimental circumstances, large changes in Akt activation may not necessarily equate to large changes in the activation/inactivation of downstream targets, and that loss of Akt activation alone may not explain the entirety of the status of insulin resistance [197]. This ‘spareness’ exhibited by Akt and other proximal signaling molecules implies that only small amounts of function of such signals may be required to elicit the physiological response.

4.3. GLUT4

Unlike IRS and Akt activation, which are components of the proximal canonical insulin signaling pathway, GLUT4 vesicle translocation to the plasma membrane does not exhibit the same ‘spareness’ as IRS and Akt activation and is therefore less debated on its importance during insulin resistance. Thus, an important finding within this report is that GLUT4 levels were consistently reduced in the most common treatment conditions from all three categories of palmitate concentrations. However, an important limitation of these measurements was that several reports did not assess membrane translocation. That said, of the reports that assessed both GLUT4 levels and glucose uptake, it appears that when GLUT4 levels were reduced, so were levels of glucose uptake.

4.4. Glucose Uptake

The final indicator of insulin sensitivity assessed in the current report is the uptake of glucose, which is not a portion of signaling cascade, but rather the mechanistic outcome of the functional cascade. Like Akt activation and GLUT4 levels, glucose uptake was consistently reduced across all three levels of palmitate treatment. And as noted above, a striking consistency between GLUT4 abundance and glucose uptake was observed across most reports that assessed both outcomes. However, important disparities across reports are worthy of consideration. For example, the duration of fasting (serum, glucose, or both) and composition of media components (high versus low glucose) both before and during the insulin stimulation experiments. Similarly, the duration of and concentration of insulin treatment also varied substantially between reports.

4.5. Limitations and Considerations

In general, the collective results from the summarized experiments align with impaired insulin signaling and are consistent with the mechanisms of lipid-induced insulin resistance, including the hypothesis that excess saturated fatty acids disrupt insulin receptor substrate (IRS1) signaling, impair phosphatidylinositol 3-kinase (PI3K)/Akt pathway activity, and reduce downstream glucose uptake [2,3]. However, it is acknowledged that the multifaceted nature of lipid toxicity in skeletal muscle (such as its capacity to promote inflammation, impair other signaling cascades, and disrupt metabolic homeostasis) are other topics worthy of comment. Therefore, a limitation of the current review is the selective scope which included only the effect of palmitate treatment on insulin signaling and glucose uptake. Future comments on the effect of palmitate treatment on markers of inflammation and metabolic dysfunction are warranted.
Additionally, several limitations are worth noting. First, the preparation and conjugation of palmitate to bovine serum albumin (BSA) is a critical step in ensuring bioavailability and reducing toxicity. This step varied across the studies, resulting in a lack of standardization. This methodological variability could influence both the magnitude and reproducibility of the observed effects. Secondly, the duration and concentration of insulin stimulation used to assess insulin responsiveness varied widely, making direct comparisons across independent studies more complex. Thirdly, C2C12 myotubes differ from primary human skeletal muscle (in vitro and in vivo) in several keyways. Moreover, the in vitro C2C12 model lacks interplay with other tissues and can only serve as a simplified model in this context. Thus, while the C2C12 myotubes are useful for insight regarding the mechanisms, findings from this model may not provide full insight into the physiological mechanisms and responses noted in human tissue. And finally, a major limitation worthy of considering is the common use of palmitate levels that far exceed pharmacokinetically attainable levels. This is important as the physiological relevance of these findings for in vivo systems is questionable. Moreover, several reports noted loss of cell viability at several of the utilized concentrations (most commonly >0.3 mM). In fact, several reports noted loss of cell viability (usually assessed via tetrazolium assay) at pharmacokinetically attainable levels [9,13,21,31,42,195], though it was more common for these lower concentrations to not affect viability. However, these observations raise questions about the off-target mechanisms of palmitate concentrations that exceeded these levels.

4.6. Strengths and Conclusions

Despite the limitations highlighted above, our review has several strengths. First, a strength of this report is the volume and consistency of the primary findings. The reliability of reduced insulin signaling following palmitate treatment despite differences in culture conditions, treatment durations, and insulin co-stimulation protocols across various studies demonstrates a high degree of reproducibility of the model. Indeed, reductions in insulin-stimulated pAkt and GLUT4 levels as well as consistently reduced insulin-stimulated glucose uptake provide convincing evidence of the reliability in palmitate-treated myotubes as a model of skeletal muscle insulin resistance. These shared features across studies emphasize and reinforce the validity and utility of the palmitate–C2C12 model as a robust in vitro system for probing mechanisms related to insulin resistance.
Collectively, this report demonstrates the highly consistent dose- and time-dependent effects of palmitate-mediated insulin resistance in the C2C12 myotube model of skeletal muscle. The findings herein may also be useful by informing future studies of in vitro models of insulin resistance and serve as a user’s reference for C2C12 myotube insulin resistance.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/nu17223619/s1, Table S1: Composite search results and inclusion/exclusion results from Pubmed and Scopus.; File S1: Raw data estimates of original research [4,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196].

Author Contributions

Conceptualization, R.A.V.; methodology, R.A.V.; investigation, J.M.Z., A.J.K., K.B.T., and R.A.V.; resources, R.A.V.; data curation, R.A.V.; writing—original draft preparation, J.M.Z., A.J.K., K.B.T., and R.A.V.; writing—review and editing, J.M.Z., A.J.K., K.B.T., and R.A.V.; visualization, R.A.V.; supervision, R.A.V.; project administration, R.A.V.; funding acquisition, R.A.V. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the Department of Health and Human Performance within the Congdon School of Health Sciences. Additional support was provided by the Congdon School of Health Sciences Summer Undergraduate Research Fellowship (SURF).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study.

Acknowledgments

The authors have reviewed and edited the output and take full responsibility for the content of this publication. All authors have read and approved the final manuscript.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
3D3 dimensional
Glut4glucose transporter member 4
GSVglut4 storage vesicles
HGhigh glucose
IκκI kappa B kinase
IRS1insulin receptor substrate 1 (protein)
IRinsulin receptor (protein)
LGlow glucose
PI3Kphosphatidylinositol 3-Kinase (protein)
PAktphosphorylated Akt
PKCprotein kinase c
ROSreactive oxygen species
SDstandard deviation
SEMstandard error of the mean
TLR4toll-like receptor 4
VCvisual confirmation

References

  1. Yudhani, R.D.; Sari, Y.; Nugrahaningsih, D.A.A.; Sholikhah, E.N.; Rochmanti, M.; Purba, A.K.R.; Khotimah, H.; Nugrahenny, D.; Mustofa, M. Insulin Resistance Model: A Recent Update. J. Obes. 2023, 2023, 1964732. [Google Scholar] [CrossRef] [PubMed]
  2. Sergi, D.; Naumovski, N.; Heilbronn, L.K.; Abeywardena, M.; O’Callaghan, N.; Lionetti, L.; Luscombe-Marsh, N. Mitochondrial (Dys)function and Insulin Resistance: From Pathophysiological Molecular Mechanisms to the Impact of Diet. Front. Physiol. 2019, 10, 532. [Google Scholar] [CrossRef]
  3. Palomer, X.; Pizarro-Delgado, J.; Barroso, E.; Vázquez-Carrera, M. Palmitic and Oleic Acid: The Yin and Yang of Fatty Acids in Type 2 Diabetes Mellitus. Trends Endocrinol. Metab. 2018, 29, 178–190. [Google Scholar] [CrossRef]
  4. Schmitz-Peiffer, C.; Craig, D.L.; Biden, T.J. Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. J. Biol. Chem. 1999, 274, 24202–24210. [Google Scholar] [CrossRef] [PubMed]
  5. Huang, X.; Tang, X.; He, Q.; Tadese, D.A.; Cao, K.; Gao, J.; Xu, Q.; Cheng, R.; Lu, Q.; Chen, Y.; et al. High-fat diet increases circulating palmitic acid produced by gut Bacteroides thetaiotaomicron to promote thrombosis. Cell Rep. Med. 2025, 6, 102260. [Google Scholar] [CrossRef] [PubMed]
  6. Normand-Lauzière, F.; Frisch, F.; Labbé, S.M.; Bherer, P.; Gagnon, R.; Cunnane, S.C.; Carpentier, A.C. Increased postprandial nonesterified fatty acid appearance and oxidation in type 2 diabetes is not fully established in offspring of diabetic subjects. PLoS ONE 2010, 5, e10956. [Google Scholar] [CrossRef]
  7. de Wilde, J.; Smit, E.; Snepvangers, F.J.; de Wit, N.W.; Mohren, R.; Hulshof, M.F.; Mariman, E.C. Adipophilin protein expression in muscle—A possible protective role against insulin resistance. FEBS J. 2010, 277, 761–773. [Google Scholar] [CrossRef]
  8. Cheon, H.G.; Cho, Y.S. Protection of palmitic acid-mediated lipotoxicity by arachidonic acid via channeling of palmitic acid into triglycerides in C2C12. J. Biomed. Sci. 2014, 21, 13. [Google Scholar] [CrossRef] [PubMed]
  9. Huang, C.Y.; Han, I.S.; Hsieh, P.S.; Tsai, M.C.; Chien, H.C. Dichloroacetate, a pyruvate dehydrogenase activator, alleviates high-fat-induced impairment of myogenic differentiation in skeletal muscles. Basic Clin. Pharmacol. Toxicol. 2025, 136, e14102. [Google Scholar] [CrossRef]
  10. Chen, X.; Xu, S.; Wei, S.; Deng, Y.; Li, Y.; Yang, F.; Liu, P. Comparative Proteomic Study of Fatty Acid-treated Myoblasts Reveals Role of Cox-2 in Palmitate-induced Insulin Resistance. Sci. Rep. 2016, 6, 21454. [Google Scholar] [CrossRef]
  11. Chavez, J.A.; Holland, W.L.; Bär, J.; Sandhoff, K.; Summers, S.A. Acid ceramidase overexpression prevents the inhibitory effects of saturated fatty acids on insulin signaling. J. Biol. Chem. 2005, 280, 20148–20153. [Google Scholar] [CrossRef] [PubMed]
  12. Na, Y.J.; Choi, K.J.; Jung, W.H.; Park, S.B.; Koh, B.; Hoe, K.L.; Kim, K.Y. Development of 3D Muscle Cell Culture-Based Screening System for Metabolic Syndrome Drug Research. Tissue Eng. Part C Methods 2025, 31, 53–64. [Google Scholar] [CrossRef]
  13. Park, S.Y.; Kim, M.H.; Ahn, J.H.; Lee, S.J.; Lee, J.H.; Eum, W.S.; Choi, S.Y.; Kwon, H.Y. The Stimulatory Effect of Essential Fatty Acids on Glucose Uptake Involves Both Akt and AMPK Activation in C2C12 Skeletal Muscle Cells. Korean J. Physiol. Pharmacol. 2014, 18, 255–261. [Google Scholar] [CrossRef]
  14. Ren, Y.; Wang, K.; Wu, Y.; Li, J.; Ma, J.; Wang, L.; Zhang, C.; Wei, Y.; Yang, Y. Lycium barbarum polysaccharide mitigates high-fat-diet-induced skeletal muscle atrophy by promoting AMPK/PINK1/Parkin-mediated mitophagy. Int. J. Biol. Macromol. 2025, 301, 140488. [Google Scholar] [CrossRef] [PubMed]
  15. Norouzi, S.; Adulcikas, J.; Henstridge, D.C.; Sonda, S.; Sohal, S.S.; Myers, S. The Zinc Transporter Zip7 Is Downregulated in Skeletal Muscle of Insulin-Resistant Cells and in Mice Fed a High-Fat Diet. Cells 2019, 8, 663. [Google Scholar] [CrossRef]
  16. Pan, X.; Liu, C.; Wang, X.; Zhao, M.; Zhang, Z.; Zhang, X.; Wang, C.; Song, G. Resveratrol improves palmitic acid-induced insulin resistance via the DDIT4/mTOR pathway in C2C12 cells. Mol. Med. Rep. 2023, 28, 181. [Google Scholar] [CrossRef]
  17. Zhang, N.; Zhou, Y.; Yuan, Q.; Gao, Y.; Wang, Y.; Wang, X.; Cui, X.; Xu, P.; Ji, C.; Guo, X.; et al. Dynamic transcriptome profile in db/db skeletal muscle reveal critical roles for long noncoding RNA regulator. Int. J. Biochem. Cell Biol. 2018, 104, 14–24. [Google Scholar] [CrossRef]
  18. Hirabara, S.M.; Curi, R.; Maechler, P. Saturated fatty acid-induced insulin resistance is associated with mitochondrial dysfunction in skeletal muscle cells. J. Cell. Physiol. 2010, 222, 187–194. [Google Scholar] [CrossRef]
  19. Zhang, Y.; Zhao, Y.P.; Gao, Y.F.; Fan, Z.M.; Liu, M.Y.; Cai, X.Y.; Xia, Z.K.; Gao, C.L. Silencing miR-106b improves palmitic acid-induced mitochondrial dysfunction and insulin resistance in skeletal myocytes. Mol. Med. Rep. 2015, 11, 3834–3841. [Google Scholar] [CrossRef] [PubMed][Green Version]
  20. Feng, X.T.; Wang, T.Z.; Leng, J.; Chen, Y.; Liu, J.B.; Liu, Y.; Wang, W.J. Palmitate contributes to insulin resistance through downregulation of the Src-mediated phosphorylation of Akt in C2C12 myotubes. Biosci. Biotechnol. Biochem. 2012, 76, 1356–1361. [Google Scholar] [CrossRef]
  21. Kopp, E.L.; Deussen, D.N.; Cuomo, R.; Lorenz, R.; Roth, D.M.; Mahata, S.K.; Patel, H.H. Modeling and Phenotyping Acute and Chronic Type 2 Diabetes Mellitus In Vitro in Rodent Heart and Skeletal Muscle Cells. Cells 2023, 12, 2786. [Google Scholar] [CrossRef]
  22. Mok, J.; Park, T.S.; Kim, S.; Kim, D.; Choi, C.S.; Park, J. Prokineticin receptor 1 ameliorates insulin resistance in skeletal muscle. FASEB J. 2021, 35, e21179. [Google Scholar] [CrossRef] [PubMed]
  23. Liu, H.-W.; Huang, W.-C.; Yu, W.-J.; Chang, S.-J. Toona sinensis ameliorates insulin resistance via AMPK and PPAR gamma pathways. Food Funct. 2015, 6, 1855–1864. [Google Scholar] [CrossRef]
  24. Kirk-Ballard, H.; Wang, Z.Q.; Acharya, P.; Zhang, X.H.; Yu, Y.; Kilroy, G.; Ribnicky, D.; Cefalu, W.T.; Floyd, Z.E. An extract of Artemisia dracunculus L. inhibits ubiquitin-proteasome activity and preserves skeletal muscle mass in a murine model of diabetes. PLoS ONE 2013, 8, e57112. [Google Scholar] [CrossRef]
  25. Gone, G.B.; Go, G.; Nam, G.; Jeong, W.; Kim, H.; Lee, S.; Chung, S.J. Exploring the Anti-Diabetic Potential of Quercetagitrin through Dual Inhibition of PTPN6 and PTPN9. Nutrients 2024, 16, 647. [Google Scholar] [CrossRef] [PubMed]
  26. Jheng, H.F.; Tsai, P.J.; Guo, S.M.; Kuo, L.H.; Chang, C.S.; Su, I.J.; Chang, C.R.; Tsai, Y.S. Mitochondrial fission contributes to mitochondrial dysfunction and insulin resistance in skeletal muscle. Mol. Cell. Biol. 2012, 32, 309–319. [Google Scholar] [CrossRef]
  27. Parvaneh, L.; Meshkani, R.; Bakhtiyari, S.; Mohammadtaghvaie, N.; Gorganifiruzjaee, S.; Taheripak, G.; Golestani, A.; Foruzandeh, M.; Larijani, B.; Taghikhani, M. Palmitate and inflammatory state additively induce the expression of PTP1B in muscle cells. Biochem. Biophys. Res. Commun. 2010, 396, 467–471. [Google Scholar] [CrossRef] [PubMed]
  28. Blackburn, M.L.; Ono-Moore, K.D.; Sobhi, H.F.; Adams, S.H. Carnitine palmitoyltransferase 2 knockout potentiates palmitate-induced insulin resistance in C2C12. Am. J. Physiol. Endocrinol. Metab. 2020, 319, E265–E275. [Google Scholar] [CrossRef]
  29. Tatebe, J.; Morita, T. Enhancement of TNF-α expression and inhibition of glucose uptake by nicotine in the presence of a free fatty acid in C2C12 skeletal myocytes. Horm. Metab. Res. 2011, 43, 11–16. [Google Scholar] [CrossRef]
  30. Gwon, H.J.; Cho, W.; Choi, S.W.; Lim, D.S.; Tanriverdi, E.; El-Aty, A.M.A.; Jeong, J.H.; Jung, T.W. Donepezil improves skeletal muscle insulin resistance in obese mice via the AMPK/FGF21-mediated suppression of inflammation and ferroptosis. Arch. Pharmacal Res. 2024, 47, 940–953. [Google Scholar] [CrossRef]
  31. Wu, C.; Zhang, C.; Li, F.; Yan, Y.; Wu, Y.; Li, B.; Tong, H.; Lang, J. Fucoxanthin Mitigates High-Fat-Induced Lipid Deposition and Insulin Resistance in Skeletal Muscle through Inhibiting PKM1 Activity. J. Agric. Food Chem. 2024, 72, 18013–18026. [Google Scholar] [CrossRef] [PubMed]
  32. Sun, J.L.; Kim, Y.J.; Cho, W.; Lim, D.S.; Gwon, H.J.; El-Aty, A.M.A.; Nas, M.A.; Jeong, J.H.; Jung, T.W. Interleukin 38 improves insulin resistance in hyperlipidemic skeletal muscle cells via PPARδ/SIRT1-mediated suppression of STAT3 signaling and oxidative stress. Biochem. Biophys. Res. Commun. 2024, 722, 150158. [Google Scholar] [CrossRef]
  33. Li, J.; Zhang, Y.; Yu, F.; Pan, Y.; Zhang, Z.; He, Y.; Yang, H.; Zhou, P. Proteoglycan Extracted from Ganoderma lucidum Ameliorated Diabetes-Induced Muscle Atrophy via the AMPK/SIRT1 Pathway In Vivo and In Vitro. ACS Omega 2023, 8, 30359–30373. [Google Scholar] [CrossRef]
  34. Oh, H.; Cho, W.; El-Aty, A.M.A.; Bayram, C.; Jeong, J.H.; Jung, T.W. Resolvin D3 improves the impairment of insulin signaling in skeletal muscle and nonalcoholic fatty liver disease through AMPK/autophagy-associated attenuation of ER stress. Biochem. Pharmacol. 2022, 203, 115203. [Google Scholar] [CrossRef]
  35. Jung, T.W.; Kim, H.; Park, S.Y.; Cho, W.; Oh, H.; Lee, H.J.; El-Aty, A.M.A.; Hacimuftuoglu, A.; Jeong, J.H. Stachydrine alleviates lipid-induced skeletal muscle insulin resistance via AMPK/HO-1-mediated suppression of inflammation and endoplasmic reticulum stress. J. Endocrinol. Investig. 2022, 45, 2181–2191. [Google Scholar] [CrossRef]
  36. Park, S.Y.; Lee, H.J.; Song, J.H.; Shin, Y.K.; El-Aty, A.M.A.; Ramadan, A.; Hacimuftuoglu, A.; Jeong, J.H.; Jung, T.W. Dimethyl itaconate attenuates palmitate-induced insulin resistance in skeletal muscle cells through the AMPK/FGF21/PPARδ-mediated suppression of inflammation. Life Sci. 2021, 287, 120129. [Google Scholar] [CrossRef]
  37. Pesta, D.; Jelenik, T.; Zaharia, O.P.; Bobrov, P.; Görgens, S.; Bódis, K.; Karusheva, Y.; Jakovljevic, N.K.; Lalic, N.M.; Markgraf, D.F.; et al. NDUFB6 Polymorphism Is Associated with Physical Activity-Mediated Metabolic Changes in Type 2 Diabetes. Front. Endocrinol. 2021, 12, 693683. [Google Scholar] [CrossRef]
  38. Jung, T.W.; Lee, H.J.; Pyun, D.H.; Kim, T.J.; Bang, J.S.; Song, J.H.; Shin, Y.K.; El-Aty, A.M.A.; Jeong, J.H. Capmatinib improves insulin sensitivity and inflammation in palmitate-treated C2C12 myocytes through the PPARδ/p38-dependent pathway. Mol. Cell Endocrinol. 2021, 534, 111364. [Google Scholar] [CrossRef] [PubMed]
  39. Kim, T.J.; Lee, H.J.; Pyun, D.H.; El-Aty, A.M.A.; Jeong, J.H.; Jung, T.W. Valdecoxib improves lipid-induced skeletal muscle insulin resistance via simultaneous suppression of inflammation and endoplasmic reticulum stress. Biochem. Pharmacol. 2021, 188, 114557. [Google Scholar] [CrossRef] [PubMed]
  40. Liu, M.; Wang, L.; Li, X.; Wu, Y.; Yin, F.; Liu, J. Trilobatin ameliorates insulin resistance through IRS-AKT-GLUT4 signaling pathway in C2C12 myotubes and ob/ob mice. Chin. Med. 2020, 15, 110. [Google Scholar] [CrossRef] [PubMed]
  41. Chiu, Y.J.; Lo, Y.H.; Yang, J.S.; Kuo, S.C.; Tsai, S.C. Curcumin Derivative MTH-3 Regulates Palmitate-induced Insulin Resistance in Mouse Myoblast C2C12 Cells. Vivo 2021, 35, 3181–3191. [Google Scholar] [CrossRef]
  42. Chuang, W.T.; Yen, C.C.; Huang, C.S.; Chen, H.W.; Lii, C.K. Benzyl Isothiocyanate Ameliorates High-Fat Diet-Induced Hyperglycemia by Enhancing Nrf2-Dependent Antioxidant Defense-Mediated IRS-1/AKT/TBC1D1 Signaling and GLUT4 Expression in Skeletal Muscle. J. Agric. Food Chem. 2020, 68, 15228–15238. [Google Scholar] [CrossRef]
  43. Park, J.; Jung, T.W.; Chung, Y.H.; Park, E.S.; Jeong, J.H. 1,2-Dilinoleoyl-sn-glycero-3-phosphocholine increases insulin sensitivity in palmitate-treated myotubes and induces lipolysis in adipocytes. Biochem. Biophys. Res. Commun. 2020, 533, 162–167. [Google Scholar] [CrossRef]
  44. Sun, J.L.; Park, J.; Lee, T.; Jeong, J.H.; Jung, T.W. DEL-1 ameliorates high-fat diet-induced insulin resistance in mouse skeletal muscle through SIRT1/SERCA2-mediated ER stress suppression. Biochem. Pharmacol. 2020, 171, 113730. [Google Scholar] [CrossRef] [PubMed]
  45. Jung, T.W.; Lee, S.H.; Kim, H.C.; Bang, J.S.; El-Aty, A.M.A.; Hacımüftüoğlu, A.; Shin, Y.K.; Jeong, J.H. METRNL attenuates lipid-induced inflammation and insulin resistance via AMPK or PPARδ-dependent pathways in skeletal muscle of mice. Exp. Mol. Med. 2018, 50, 1–11. [Google Scholar] [CrossRef] [PubMed]
  46. Kulabas, S.S.; Ipek, H.; Tufekci, A.R.; Arslan, S.; Demirtas, I.; Ekren, R.; Sezerman, U.; Tumer, T.B. Ameliorative potential of Lavandula stoechas in metabolic syndrome via multitarget interactions. J. Ethnopharmacol. 2018, 223, 88–98. [Google Scholar] [CrossRef]
  47. Yang, M.; Wei, D.; Mo, C.; Zhang, J.; Wang, X.; Han, X.; Wang, Z.; Xiao, H. Saturated fatty acid palmitate-induced insulin resistance is accompanied with myotube loss and the impaired expression of health benefit myokine genes in C2C12 myotubes. Lipids Health Dis. 2013, 12, 104. [Google Scholar] [CrossRef] [PubMed]
  48. Jung, T.W.; Hwang, H.J.; Hong, H.C.; Yoo, H.J.; Baik, S.H.; Choi, K.M. BAIBA attenuates insulin resistance and inflammation induced by palmitate or a high fat diet via an AMPK-PPARδ-dependent pathway in mice. Diabetologia 2015, 58, 2096–2105. [Google Scholar] [CrossRef]
  49. Jung, T.W.; Kim, H.C.; El-Aty, A.M.A.; Jeong, J.H. Protectin DX ameliorates palmitate- or high-fat diet-induced insulin resistance and inflammation through an AMPK-PPARα-dependent pathway in mice. Sci. Rep. 2017, 7, 1397. [Google Scholar] [CrossRef]
  50. Yang, C.; Aye, C.C.; Li, X.; Ramos, A.D.; Zorzano, A.; Mora, S. Mitochondrial dysfunction in insulin resistance: Differential contributions of chronic insulin and saturated fatty acid exposure in muscle cells. Biosci. Rep. 2012, 32, 465–478. [Google Scholar] [CrossRef]
  51. Pyun, D.H.; Kim, T.J.; Park, S.Y.; Lee, H.J.; El-Aty, A.M.A.; Jeong, J.H.; Jung, T.W. Patchouli alcohol ameliorates skeletal muscle insulin resistance and NAFLD via AMPK/SIRT1-mediated suppression of inflammation. Mol. Cell Endocrinol. 2021, 538, 111464. [Google Scholar] [CrossRef] [PubMed]
  52. Jung, T.W.; Park, J.; Sun, J.L.; Ahn, S.H.; Abd El-Aty, A.M.; Hacimuftuoglu, A.; Kim, H.C.; Shim, J.H.; Shin, S.; Jeong, J.H. Administration of kynurenic acid reduces hyperlipidemia-induced inflammation and insulin resistance in skeletal muscle and adipocytes. Mol. Cell Endocrinol. 2020, 518, 110928. [Google Scholar] [CrossRef]
  53. de Figueiredo, A.S.P.; Salmon, A.B.; Bruno, F.; Jimenez, F.; Martinez, H.G.; Halade, G.V.; Ahuja, S.S.; Clark, R.A.; DeFronzo, R.A.; Abboud, H.E.; et al. Nox2 mediates skeletal muscle insulin resistance induced by a high fat diet. J. Biol. Chem. 2015, 290, 13427–13439. [Google Scholar] [CrossRef]
  54. Zhao, M.; Zhang, Z.F.; Ding, Y.; Wang, J.B.; Li, Y. Astragalus polysaccharide improves palmitate-induced insulin resistance by inhibiting PTP1B and NF-κB in C2C12 myotubes. Molecules 2012, 17, 7083–7092. [Google Scholar] [CrossRef]
  55. Kim, J.; Son, J.; Ahn, D.; Nam, G.; Zhao, X.; Park, H.; Jeong, W.; Chung, S.J. Structure-Activity Relationship of Synthetic Ginkgolic Acid Analogs for Treating Type 2 Diabetes by PTPN9 Inhibition. Int. J. Mol. Sci. 2022, 23, 3927. [Google Scholar] [CrossRef] [PubMed]
  56. Cruz, A.M.; Beall, C. Extracellular ATP Increases Glucose Metabolism in Skeletal Muscle Cells in a P2 Receptor Dependent Manner but Does Not Contribute to Palmitate-Induced Insulin Resistance. Front. Physiol. 2020, 11, 567378. [Google Scholar] [CrossRef] [PubMed]
  57. Bosquet, A.; Girona, J.; Guaita-Esteruelas, S.; Heras, M.; Saavedra-García, P.; Martínez-Micaelo, N.; Masana, L.; Rodríguez-Calvo, R. FABP4 inhibitor BMS309403 decreases saturated-fatty-acid-induced endoplasmic reticulum stress-associated inflammation in skeletal muscle by reducing p38 MAPK activation. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids 2018, 1863, 604–613. [Google Scholar] [CrossRef]
  58. Lee, J.S.; Park, J.M.; Lee, S.; Lee, H.J.; Yang, H.S.; Yeo, J.; Lee, K.R.; Choi, B.H.; Hong, E.K. Hispidin rescues palmitate-induced insulin resistance in C2C12 myotubes. Mol. Med. Rep. 2017, 16, 4229–4234. [Google Scholar] [CrossRef][Green Version]
  59. Zhou, Q.; Du, J.; Hu, Z.; Walsh, K.; Wang, X.H. Evidence for adipose-muscle cross talk: Opposing regulation of muscle proteolysis by adiponectin and Fatty acids. Endocrinology 2007, 148, 5696–5705. [Google Scholar] [CrossRef]
  60. Hassan, R.H.; Hainault, I.; Vilquin, J.T.; Samama, C.; Lasnier, F.; Ferre, P.; Foufelle, F.; Hajduch, E. Endoplasmic reticulum stress does not mediate palmitate-induced insulin resistance in mouse and human muscle cells. Diabetologia 2012, 55, 204–214. [Google Scholar] [CrossRef]
  61. Zhang, J.; Wu, W.; Li, D.; Guo, Y.; Ding, H. Overactivation of NF-κB impairs insulin sensitivity and mediates palmitate-induced insulin resistance in C2C12 skeletal muscle cells. Endocrine 2010, 37, 157–166. [Google Scholar] [CrossRef]
  62. Qin, H.; Liu, Y.; Lu, N.; Li, Y.; Sun, C.H. cis-9,trans-11-Conjugated linoleic acid activates AMP-activated protein kinase in attenuation of insulin resistance in C2C12 myotubes. J. Agric. Food Chem. 2009, 57, 4452–4458. [Google Scholar] [CrossRef] [PubMed]
  63. Chang, Y.C.; Liu, H.W.; Chen, Y.T.; Chen, Y.A.; Chen, Y.J.; Chang, S.J. Resveratrol protects muscle cells against palmitate-induced cellular senescence and insulin resistance through ameliorating autophagic flux. J. Food Drug Anal. 2018, 26, 1066–1074. [Google Scholar] [CrossRef] [PubMed]
  64. Li, Q.; Jiang, X.; Zhou, Y.; Gu, Y.; Ding, Y.; Luo, J.; Pang, N.; Sun, Y.; Pei, L.; Pan, J.; et al. Improving Mitochondrial Function in Skeletal Muscle Contributes to the Amelioration of Insulin Resistance by Nicotinamide Riboside. Int. J. Mol. Sci. 2023, 24, 10015. [Google Scholar] [CrossRef] [PubMed]
  65. Yu, M.; Wu, S.; Gong, C.; Chen, L. Neuregulin-1β increases glucose uptake and promotes GLUT4 translocation in palmitate-treated C2C12 myotubes by activating PI3K/AKT signaling pathway. Front. Pharmacol. 2023, 13, 1066279. [Google Scholar] [CrossRef]
  66. Jiao, Y.; Williams, A.; Wei, N. Quercetin ameliorated insulin resistance via regulating METTL3-mediated N6-methyladenosine modification of PRKD2 mRNA in skeletal muscle and C2C12 myocyte cell line. Nutr. Metab. Cardiovasc. Dis. 2022, 32, 2655–2668. [Google Scholar] [CrossRef]
  67. He, Q.; Chen, B.; Wang, G.; Zhou, D.; Zeng, H.; Li, X.; Song, Y.; Yu, X.; Liang, W.; Chen, H.; et al. Co-Crystal of Rosiglitazone With Berberine Ameliorates Hyperglycemia and Insulin Resistance Through the PI3K/AKT/TXNIP Pathway. Front. Pharmacol. 2022, 13, 842879. [Google Scholar] [CrossRef]
  68. Hu, M.M.; Zheng, W.Y.; Cheng, M.H.; Song, Z.Y.; Shaukat, H.; Atta, M.; Qin, H. Sesamol Reverses Myofiber-Type Conversion in Obese States via Activating the SIRT1/AMPK Signal Pathway. J. Agric. Food Chem. 2022, 70, 2253–2264. [Google Scholar] [CrossRef]
  69. Nan, J.; Lee, J.S.; Lee, S.A.; Lee, D.S.; Park, K.S.; Chung, S.S. An Essential Role of the N-Terminal Region of ACSL1 in Linking Free Fatty Acids to Mitochondrial β-Oxidation in C2C12 Myotubes. Mol. Cells 2021, 44, 637–646. [Google Scholar] [CrossRef]
  70. Shen, S.; Liao, Q.; Zhang, T.; Pan, R.; Lin, L. Myricanol modulates skeletal muscle-adipose tissue crosstalk to alleviate high-fat diet-induced obesity and insulin resistance. Br. J. Pharmacol. 2019, 176, 3983–4001. [Google Scholar] [CrossRef]
  71. Zhang, Q.; Kong, X.; Yuan, H.; Guan, H.; Li, Y.; Niu, Y. Mangiferin Improved Palmitate-Induced-Insulin Resistance by Promoting Free Fatty Acid Metabolism in HepG2 and C2C12 Cells via PPARα: Mangiferin Improved Insulin Resistance. J. Diabetes Res. 2019, 2019, 2052675. [Google Scholar] [CrossRef]
  72. Fujiwara, Y.; Tsukahara, C.; Ikeda, N.; Sone, Y.; Ishikawa, T.; Ichi, I.; Koike, T.; Aoki, Y. Oleuropein improves insulin resistance in skeletal muscle by promoting the translocation of GLUT4. J. Clin. Biochem. Nutr. 2017, 61, 196–202. [Google Scholar] [CrossRef]
  73. Lee, S.J.; Choi, S.E.; Lee, H.B.; Song, M.W.; Kim, Y.H.; Jeong, J.Y.; Kang, Y.; Kim, H.J.; Kim, T.H.; Jeon, J.Y.; et al. A Class I Histone Deacetylase Inhibitor Attenuates Insulin Resistance and Inflammation in Palmitate-Treated C2C12 Myotubes and Muscle of HF/HFr Diet Mice. Front. Pharmacol. 2020, 11, 601448. [Google Scholar] [CrossRef]
  74. Chien, H.C.; Greenhaff, P.L.; Constantin-Teodosiu, D. PPARδ and FOXO1 Mediate Palmitate-Induced Inhibition of Muscle Pyruvate Dehydrogenase Complex and CHO Oxidation, Events Reversed by Electrical Pulse Stimulation. Int. J. Mol. Sci. 2020, 21, 5942. [Google Scholar] [CrossRef]
  75. Smimmo, M.; Casale, V.; D’Andrea, D.; Bello, I.; Iaccarino, N.; Romano, F.; Brancaleone, V.; Panza, E.; Bianca, R.D.d.V.; Katsouda, A.; et al. Defective protein persulfidation is involved in obesity associated skeletal muscle dysfunction: Role of SIRT-1. Redox Biol. 2025, 83, 103645. [Google Scholar] [CrossRef] [PubMed]
  76. Yang, J.M.; Han, I.S.; Chen, T.H.; Hsieh, P.S.; Tsai, M.C.; Chien, H.C. Pharmacological activation of pyruvate dehydrogenase by dichloroacetate protects against obesity-induced muscle atrophy in vitro and in vivo. Eur. J. Pharmacol. 2024, 979, 176854. [Google Scholar] [CrossRef] [PubMed]
  77. Mao, L.; Xie, Q.; Cheng, Q.; Tang, W.; Mao, L. EPA but not DHA improve systemic IR through activating muscle IL-6/AMPK pathway in high-fat diet-fed mice. J. Funct. Foods 2025, 127, 106749. [Google Scholar] [CrossRef]
  78. Kwon, B.; Querfurth, H.W. Palmitate activates mTOR/p70S6K through AMPK inhibition and hypophosphorylation of raptor in skeletal muscle cells: Reversal by oleate is similar to metformin. Biochimie 2015, 118, 141–150. [Google Scholar] [CrossRef] [PubMed]
  79. Chen, X.; Zhao, X.; Lan, F.; Zhou, T.; Cai, H.; Sun, H.; Kong, W. Hydrogen Sulphide Treatment Increases Insulin Sensitivity and Improves Oxidant Metabolism through the CaMKKbeta-AMPK Pathway in PA-Induced IR C2C12 Cells. Sci. Rep. 2017, 7, 13248. [Google Scholar] [CrossRef]
  80. Tardif, N.; Salles, J.; Guillet, C.; Tordjman, J.; Reggio, S.; Landrier, J.F.; Giraudet, C.; Patrac, V.; Bertrand-Michel, J.; Migne, C.; et al. Muscle ectopic fat deposition contributes to anabolic resistance in obese sarcopenic old rats through eIF2α activation. Aging Cell 2014, 13, 1001–1011. [Google Scholar] [CrossRef]
  81. Dai, F.; Jiang, T.; Bao, Y.Y.; Chen, G.J.; Chen, L.; Zhang, Q.; Lu, Y.X. Fenofibrate improves high-fat diet-induced and palmitate-induced endoplasmic reticulum stress and inflammation in skeletal muscle. Life Sci. 2016, 157, 158–167. [Google Scholar] [CrossRef]
  82. D’Souza, K.; Mercer, A.; Mawhinney, H.; Pulinilkunnil, T.; Udenigwe, C.C.; Kienesberger, P.C. Whey Peptides Stimulate Differentiation and Lipid Metabolism in Adipocytes and Ameliorate Lipotoxicity-Induced Insulin Resistance in Muscle Cells. Nutrients 2020, 12, 425. [Google Scholar] [CrossRef]
  83. Zhang, C.; Li, S.; Li, L.; Wang, R.; Luo, S.; Li, G. Stevioside Ameliorates Palmitic Acid-Induced Abnormal Glucose Uptake via the PDK4/AMPK/TBC1D1 Pathway in C2C12 Myotubes. Endocrinol. Diabetes Metab. 2024, 7, e00482. [Google Scholar] [CrossRef]
  84. Jakovljevic, N.K.; Pavlovic, K.; Zujovic, T.; Kravic-Stevovic, T.; Jotic, A.; Markovic, I.; Lalic, N.M. In vitro models of insulin resistance: Mitochondrial coupling is differently affected in liver and muscle cells. Mitochondrion 2021, 61, 165–173. [Google Scholar] [CrossRef] [PubMed]
  85. Wu, P.; Wang, Q.; Jiang, C.; Chen, C.; Liu, Y.; Chen, Y.; Zeng, Y. MicroRNA-29a is involved lipid metabolism dysfunction and insulin resistance in C2C12 myotubes by targeting PPARδ. Mol. Med. Rep. 2018, 17, 8493–8501. [Google Scholar] [CrossRef]
  86. Fan, Z.; Wu, J.; Chen, Q.N.; Lyu, A.K.; Chen, J.L.; Sun, Y.; Lyu, Q.; Zhao, Y.X.; Guo, A.; Liao, Z.Y.; et al. Type 2 diabetes-induced overactivation of P300 contributes to skeletal muscle atrophy by inhibiting autophagic flux. Life Sci. 2020, 258, 118243. [Google Scholar] [CrossRef] [PubMed]
  87. Nieuwoudt, S.; Mulya, A.; Fealy, C.E.; Martelli, E.; Dasarathy, S.; Prasad, S.V.N.; Kirwan, J.P. In vitro contraction protects against palmitate-induced insulin resistance in C2C12 myotubes. Am. J. Physiol. Cell Physiol. 2017, 313, C575–C583. [Google Scholar] [CrossRef] [PubMed]
  88. Kim, J.S.; Lee, H.; Jung, C.H.; Lee, S.J.; Ha, T.Y.; Ahn, J. Chicoric acid mitigates impaired insulin sensitivity by improving mitochondrial function. Biosci. Biotechnol. Biochem. 2018, 82, 1197–1206. [Google Scholar] [CrossRef]
  89. Li, Z.-Y.; Na, H.-M.; Peng, G.; Pu, J.; Liu, P. Alteration of microRNA expression correlates to fatty acid-mediated insulin resistance in mouse myotblasts. Mol. Biosyst. 2011, 7, 871–877. [Google Scholar] [CrossRef]
  90. Zhou, X.; Chen, J.; Wang, F.; Yang, H.; Yang, R.; Wang, X.; Wang, Y. Selenium-enriched exopolysaccharides improve skeletal muscle glucose uptake of diabetic KKAy mice via AMPK pathway. J. Physiol. Biochem. 2014, 70, 547–554. [Google Scholar] [CrossRef]
  91. Paez, H.G.; Ferrandi, P.J.; Pitzer, C.R.; Mohamed, J.S.; Alway, S.E. Loss of NOR-1 represses muscle metabolism through mTORC1-mediated signaling and mitochondrial gene expression in C2C12 myotubes. FASEB J. 2023, 37, e23050. [Google Scholar] [CrossRef]
  92. Jia, X.K.; Huang, J.F.; Huang, X.Q.; Li, X.Y.; Huang, M.Q.; Zhu, H.C.; Li, G.P.; Lan, M.L.; Yu, Z.W.; Xu, W.; et al. Alismatis Rhizoma Triterpenes Alleviate High-Fat Diet-Induced Insulin Resistance in Skeletal Muscle of Mice. Evid. Based Complement. Alternat Med. 2021, 2021, 8857687. [Google Scholar] [CrossRef]
  93. Rustamov, J.; Roh, Y.S.; Hong, J.T.; Yoo, H.S. GT-11 impairs insulin signaling through modulation of sphingolipid metabolism in C2C12 myotubes. Life Sci. 2024, 342, 122534. [Google Scholar] [CrossRef]
  94. Pinel, A.; Rigaudière, J.P.; Jouve, C.; Capel, F. Modulation of Insulin Resistance and the Adipocyte-Skeletal Muscle Cell Cross-Talk by LCn-3PUFA. Int. J. Mol. Sci. 2018, 19, 2778. [Google Scholar] [CrossRef] [PubMed]
  95. Aoki, H.; Hanayama, M.; Mori, K.; Sato, R. Grifola frondosa (Maitake) extract activates PPARδ and improves glucose intolerance in high-fat diet-induced obese mice. Biosci. Biotechnol. Biochem. 2018, 82, 1550–1559. [Google Scholar] [CrossRef]
  96. Botteri, G.; Salvadó, L.; Gumà, A.; Hamilton, D.L.; Meakin, P.J.; Montagut, G.; Ashford, M.L.J.; Ceperuelo-Mallafré, V.; Fernández-Veledo, S.; Vendrell, J.; et al. The BACE1 product sAPPβ induces ER stress and inflammation and impairs insulin signaling. Metabolism 2018, 85, 59–75. [Google Scholar] [CrossRef]
  97. Li, Z.; Zhu, Y.; Li, C.; Tang, Y.; Jiang, Z.; Yang, M.; Ni, C.L.; Li, D.; Chen, L.; Niu, W. Liraglutide ameliorates palmitate-induced insulin resistance through inhibiting the IRS-1 serine phosphorylation in mouse skeletal muscle cells. J. Endocrinol. Investig. 2018, 41, 1097–1102. [Google Scholar] [CrossRef]
  98. Qin, X.; Li, X.; Liu, C.; Chen, Z. A novel mechanism of pre-transplant insulin resistance contributing to post-transplant complications: Cyclosporin A-induced O-GlcNAcylation. Biochem. Biophys. Res. Commun. 2017, 492, 172–177. [Google Scholar] [CrossRef] [PubMed]
  99. Capel, F.; Cheraiti, N.; Acquaviva, C.; Hénique, C.; Bertrand-Michel, J.; Vianey-Saban, C.; Prip-Buus, C.; Morio, B. Oleate dose-dependently regulates palmitate metabolism and insulin signaling in C2C12 myotubes. Biochim. Biophys. Acta 2016, 1861, 2000–2010. [Google Scholar] [CrossRef] [PubMed]
  100. Park, M.; Kaddai, V.; Ching, J.; Fridianto, K.T.; Sieli, R.J.; Sugii, S.; Summers, S.A. A Role for Ceramides, but Not Sphingomyelins, as Antagonists of Insulin Signaling and Mitochondrial Metabolism in C2C12 Myotubes. J. Biol. Chem. 2016, 291, 23978–23988. [Google Scholar] [CrossRef] [PubMed]
  101. Pinel, A.; Rigaudière, J.P.; Laillet, B.; Pouyet, C.; Malpuech-Brugère, C.; Prip-Buus, C.; Morio, B.; Capel, F. N-3PUFA differentially modulate palmitate-induced lipotoxicity through alterations of its metabolism in C2C12 muscle cells. Biochim. Biophys. Acta 2016, 1861, 12–20. [Google Scholar] [CrossRef]
  102. Capel, F.; Acquaviva, C.; Pitois, E.; Laillet, B.; Rigaudière, J.P.; Jouve, C.; Pouyet, C.; Gladine, C.; Comte, B.; Saban, C.V.; et al. DHA at nutritional doses restores insulin sensitivity in skeletal muscle by preventing lipotoxicity and inflammation. J. Nutr. Biochem. 2015, 26, 949–959. [Google Scholar] [CrossRef]
  103. Salvadó, L.; Coll, T.; Gómez-Foix, A.M.; Salmerón, E.; Barroso, E.; Palomer, X.; Vázquez-Carrera, M. Oleate prevents saturated-fatty-acid-induced ER stress, inflammation and insulin resistance in skeletal muscle cells through an AMPK-dependent mechanism. Diabetologia 2013, 56, 1372–1382. [Google Scholar] [CrossRef]
  104. Jing, Y.Y.; Li, D.; Wu, F.; Gong, L.L.; Li, R. GDF11 does not improve the palmitate induced insulin resistance in C2C12. Eur. Rev. Med. Pharmacol. Sci. 2017, 21, 1795–1802. [Google Scholar]
  105. Karimfar, M.H.; Haghani, K.; Babakhani, A.; Bakhtiyari, S. Rosiglitazone, but not epigallocatechin-3-gallate, attenuates the decrease in PGC-1α protein levels in palmitate-induced insulin-resistant C2C12 cells. Lipids 2015, 50, 521–528. [Google Scholar] [CrossRef] [PubMed]
  106. Bakhtiyari, S.; Meshkani, R.; Taghikhani, M.; Larijani, B.; Adeli, K. Protein tyrosine phosphatase-1B (PTP-1B) knockdown improves palmitate-induced insulin resistance in C2C12 skeletal muscle cells. Lipids 2010, 45, 237–244. [Google Scholar] [CrossRef] [PubMed]
  107. Jové, M.; Planavila, A.; Laguna, J.C.; Vázquez-Carrera, M. Palmitate-induced interleukin 6 production is mediated by protein kinase C and nuclear-factor kappaB activation and leads to glucose transporter 4 down-regulation in skeletal muscle cells. Endocrinology 2005, 146, 3087–3095. [Google Scholar] [CrossRef] [PubMed]
  108. Henique, C.; Mansouri, A.; Fumey, G.; Lenoir, V.; Girard, J.; Bouillaud, F.; Prip-Buus, C.; Cohen, I. Increased mitochondrial fatty acid oxidation is sufficient to protect skeletal muscle cells from palmitate-induced apoptosis. J. Biol. Chem. 2010, 285, 36818–36827. [Google Scholar] [CrossRef]
  109. Coll, T.; Alvarez-Guardia, D.; Barroso, E.; Gómez-Foix, A.M.; Palomer, X.; Laguna, J.C.; Vázquez-Carrera, M. Activation of peroxisome proliferator-activated receptor-δ by GW501516 prevents fatty acid-induced nuclear factor-κB activation and insulin resistance in skeletal muscle cells. Endocrinology 2010, 151, 1560–1569. [Google Scholar] [CrossRef]
  110. Feng, X.T.; Wang, T.Z.; Chen, Y.; Liu, J.B.; Liu, Y.; Wang, W.J. Pollen Typhae total flavone improves insulin-induced glucose uptake through the β-arrestin-2-mediated signaling in C2C12 myotubes. Int. J. Mol. Med. 2012, 30, 914–922. [Google Scholar] [CrossRef]
  111. Gorgani-Firuzjaee, S.; Bakhtiyari, S.; Golestani, A.; Meshkani, R. Leukocyte antigen-related inhibition attenuates palmitate-induced insulin resistance in muscle cells. J. Endocrinol. 2012, 215, 71–77. [Google Scholar] [CrossRef]
  112. Li, T.; Lv, Q.; Liu, C.; Li, C.; Xie, X.; Zhang, W. The Lipophilic Extract from Ginkgo biloba L. Leaves Promotes Glucose Uptake and Alleviates Palmitate-Induced Insulin Resistance in C2C12 Myotubes. Molecules 2024, 29, 1605. [Google Scholar] [CrossRef]
  113. Aswad, H.; Forterre, A.; Wiklander, O.P.; Vial, G.; Danty-Berger, E.; Jalabert, A.; Lamazière, A.; Meugnier, E.; Pesenti, S.; Ott, C.; et al. Exosomes participate in the alteration of muscle homeostasis during lipid-induced insulin resistance in mice. Diabetologia 2014, 57, 2155–2164. [Google Scholar] [CrossRef]
  114. Rivera, M.E.; Vaughan, R.A. Comparing the effects of palmitate, insulin, and palmitate-insulin co-treatment on myotube metabolism and insulin resistance. Lipids 2021, 56, 563–578. [Google Scholar] [CrossRef]
  115. Wu, S.J.; Tung, Y.J.; Ng, L.T. Anti-diabetic effects of Grifola frondosa bioactive compound and its related molecular signaling pathways in palmitate-induced C2C12 cells. J. Ethnopharmacol. 2020, 260, 112962. [Google Scholar] [CrossRef]
  116. Song, L.; Huang, K.; Tian, D.; Liu, X.; Huang, R.; Luo, J.; Zhang, M.; Lu, J.; Gui, M.; Ma, X. Epicatechin ameliorates palmitate-induced insulin resistance in C2C12 myogenic cells by alleviating oxidative stress and activating the AMPK/ACC pathway. CyTA J. Food 2024, 22, 2401591. [Google Scholar] [CrossRef]
  117. Shree, N.; Bhonde, R.R. Conditioned Media from Adipose Tissue Derived Mesenchymal Stem Cells Reverse Insulin Resistance in Cellular Models. J. Cell. Biochem. 2017, 118, 2037–2043. [Google Scholar] [CrossRef] [PubMed]
  118. Li, A.; Shen, P.; Liu, S.; Wang, J.; Zeng, J.; Du, C. Vitamin D alleviates skeletal muscle loss and insulin resistance by inducing vitamin D receptor expression and regulating the AMPK/SIRT1 signaling pathway in mice. Food Sci. Technol. 2022, 42, e47921. [Google Scholar] [CrossRef]
  119. Silva, G.; Silva, S.S.D.; Guimarães, D.S.P.S.; Cruz, M.V.D.; Silveira, L.R.; Rocha-Vieira, E.; Amorim, F.T.; Magalhaes, F.d.C. The dose-effect response of combined red and infrared photobiomodulation on insulin resistance in skeletal muscle cells. Biochem. Biophys. Rep. 2024, 40, 101831. [Google Scholar] [CrossRef]
  120. Li, H.Y.; Li, C.F.; Liu, C.H.; Chen, S.C.; Liu, Y.F.; Lv, Q.H.; Zhang, W. Extract of Phyllanthus emblica L. fruit stimulates basal glucose uptake and ameliorates palmitate-induced insulin resistance through AMPK activation in C2C12 myotubes. BMC Complement. Med. Ther. 2024, 24, 296. [Google Scholar] [CrossRef]
  121. Guo, Q.; Zhang, B.; Du, H.; Zhu, R.; Sun, X.; Fan, X.; Wei, X.; Yang, D.; Oh, Y.; Fan, L.; et al. High-fat diet and palmitate inhibits FNDC5 expression via AMPK-Zfp57 pathway in mouse muscle cells. Chem. Biol. Interact. 2023, 369, 110265. [Google Scholar] [CrossRef] [PubMed]
  122. Eo, H.; Valentine, R.J. Saturated Fatty Acid-Induced Endoplasmic Reticulum Stress and Insulin Resistance Are Prevented by Imoxin in C2C12 Myotubes. Front. Physiol. 2022, 13, 842819. [Google Scholar] [CrossRef]
  123. Rios-Morales, M.; Vieira-Lara, M.A.; Homan, E.; Langelaar-Makkinje, M.; Gerding, A.; Li, Z.; Huijkman, N.; Rensen, P.C.N.; Wolters, J.C.; Reijngoud, D.J.; et al. Butyrate oxidation attenuates the butyrate-induced improvement of insulin sensitivity in myotubes. Biochim. Biophys. Acta Mol. Basis Dis. 2022, 1868, 166476. [Google Scholar] [CrossRef]
  124. Li, B.; Ye, J.; Liu, R.; Weng, L.; Cao, Y.; Jia, S.; Xu, C.; Liu, Y.; Yan, S.; Zheng, M. Programmed cell death 5 improves skeletal muscle insulin resistance by inhibiting IRS-1 ubiquitination through stabilization of MDM2. Life Sci. 2021, 285, 119918. [Google Scholar] [CrossRef] [PubMed]
  125. Rodrigues, A.C.; Spagnol, A.R.; Frias, F.T.; de Mendonça, M.; Araújo, H.N.; Guimarães, D.; Silva, W.J.; Bolin, A.P.; Murata, G.M.; Silveira, L. Intramuscular Injection of miR-1 Reduces Insulin Resistance in Obese Mice. Front. Physiol. 2021, 12, 676265. [Google Scholar] [CrossRef]
  126. Muñoz, V.R.; Gaspar, R.C.; Severino, M.B.; Macêdo, A.P.A.; Simabuco, F.M.; Ropelle, E.R.; Cintra, D.E.; da Silva, A.S.R.; Kim, Y.B.; Pauli, J.R. Exercise Counterbalances Rho/ROCK2 Signaling Impairment in the Skeletal Muscle and Ameliorates Insulin Sensitivity in Obese Mice. Front. Immunol. 2021, 12, 702025. [Google Scholar] [CrossRef]
  127. Guo, A.; Li, K.; Tian, H.C.; Fan, Z.; Chen, Q.N.; Yang, Y.F.; Yu, J.; Wu, Y.X.; Xiao, Q. FGF19 protects skeletal muscle against obesity-induced muscle atrophy, metabolic derangement and abnormal irisin levels via the AMPK/SIRT-1/PGC-α pathway. J. Cell Mol. Med. 2021, 25, 3585–3600. [Google Scholar] [CrossRef]
  128. Luo, J.; Hou, Y.; Xie, M.; Ma, W.; Shi, D.; Jiang, B. CYC31, A Natural Bromophenol PTP1B Inhibitor, Activates Insulin Signaling and Improves Long Chain-Fatty Acid Oxidation in C2C12 Myotubes. Mar. Drugs 2020, 18, 267. [Google Scholar] [CrossRef] [PubMed]
  129. Chen, C.C.; Lee, T.Y.; Leu, Y.L.; Wang, S.H. Pigment epithelium-derived factor inhibits adipogenesis in 3T3-L1 adipocytes and protects against high-fat diet-induced obesity and metabolic disorders in mice. Transl. Res. 2019, 210, 26–42. [Google Scholar] [CrossRef]
  130. Guo, Q.; Wei, X.; Hu, H.; Yang, D.; Zhang, B.; Fan, X.; Liu, J.; He, H.; Oh, Y.; Wu, Q.; et al. The saturated fatty acid palmitate induces insulin resistance through Smad3-mediated down-regulation of FNDC5 in myotubes. Biochem. Biophys. Res. Commun. 2019, 520, 619–626. [Google Scholar] [CrossRef]
  131. Liu, Q.; Li, R.; Chen, G.; Wang, J.; Hu, B.; Li, C.; Zhu, X.; Lu, Y. Inhibitory effect of 17β-estradiol on triglyceride synthesis in skeletal muscle cells is dependent on ESR1 and not ESR2. Mol. Med. Rep. 2019, 19, 5087–5096. [Google Scholar] [CrossRef]
  132. Bakhtiyari, S.; Zaherara, M.; Haghani, K.; Khatami, M.; Rashidinejad, A. The Phosphorylation of IRS1S307 and AktS473 Molecules in Insulin-Resistant C2C12 Cells Induced with Palmitate Is Influenced by Epigallocatechin Gallate from Green Tea. Lipids 2019, 54, 141–148. [Google Scholar] [CrossRef]
  133. Huang, S.; Wang, X.; Zhang, Q.; Liu, J.; Leng, Y. Downregulation of lipin-1 induces insulin resistance by increasing intracellular ceramide accumulation in C2C12 myotubes. Int. J. Biol. Sci. 2017, 13, 1–12. [Google Scholar] [CrossRef] [PubMed]
  134. Dziewulska, A.; Dobrzyn, P.; Jazurek, M.; Pyrkowska, A.; Ntambi, J.M.; Dobrzyn, A. Monounsaturated fatty acids are required for membrane translocation of protein kinase C-theta induced by lipid overload in skeletal muscle. Mol. Membr. Biol. 2012, 29, 309–320. [Google Scholar] [CrossRef]
  135. Yoon, S.Y.; Yu, J.S.; Hwang, J.Y.; So, H.M.; Seo, S.O.; Kim, J.K.; Jang, T.S.; Chung, S.J.; Kim, K.H. Phloridzin Acts as an Inhibitor of Protein-Tyrosine Phosphatase MEG2 Relevant to Insulin Resistance. Molecules 2021, 26, 1612. [Google Scholar] [CrossRef] [PubMed]
  136. Lee, C.H.; Chiang, C.F.; Lin, F.H.; Kuo, F.C.; Su, S.C.; Huang, C.L.; Li, P.F.; Liu, J.S.; Lu, C.H.; Hsieh, C.H.; et al. PDIA4, a new endoplasmic reticulum stress protein, modulates insulin resistance and inflammation in skeletal muscle. Front. Endocrinol. 2022, 13, 1053882. [Google Scholar] [CrossRef] [PubMed]
  137. Abe, T.; Hirasaka, K.; Kohno, S.; Tomida, C.; Haruna, M.; Uchida, T.; Ohno, A.; Oarada, M.; Teshima-Kondo, S.; Okumura, Y.; et al. Capric Acid Up-Regulates UCP3 Expression without PDK4 Induction in Mouse C2C12 Myotubes. J. Nutr. Sci. Vitaminol. 2016, 62, 32–39. [Google Scholar] [CrossRef]
  138. Tang, H.; Deng, S.; Cai, J.-G.; Ma, X.-N.; Liu, M.; Zhou, L. Muscle-derived IL-6 improved insulin resistance of C2C12 cells through activating AMPK and inhibiting p38MAPK signal pathway in vitro. Int. J. Diabetes Dev. Ctries. 2019, 39, 486–498. [Google Scholar] [CrossRef]
  139. Rieusset, J.; Chauvin, M.A.; Durand, A.; Bravard, A.; Laugerette, F.; Michalski, M.C.; Vidal, H. Reduction of endoplasmic reticulum stress using chemical chaperones or Grp78 overexpression does not protect muscle cells from palmitate-induced insulin resistance. Biochem. Biophys. Res. Commun. 2012, 417, 439–445. [Google Scholar] [CrossRef]
  140. Deng, Y.T.; Chang, T.W.; Lee, M.S.; Lin, J.K. Suppression of free fatty acid-induced insulin resistance by phytopolyphenols in C2C12 mouse skeletal muscle cells. J. Agric. Food Chem. 2012, 60, 1059–1066. [Google Scholar] [CrossRef]
  141. de Hart, N.M.; Petrocelli, J.J.; Nicholson, R.J.; Yee, E.M.; Ferrara, P.J.; Bastian, E.D.; Ward, L.S.; Petersen, B.L.; Summers, S.A.; Drummond, M.J. Palmitate-Induced Inflammation and Myotube Atrophy in C2C12 Cells Are Prevented by the Whey Bioactive Peptide, Glycomacropeptide. J. Nutr. 2023, 153, 2915–2928. [Google Scholar] [CrossRef] [PubMed]
  142. Wang, C.; Liu, M.; Riojas, R.A.; Xin, X.; Gao, Z.; Zeng, R.; Wu, J.; Dong, L.Q.; Liu, F. Protein kinase C θ (PKCθ)-dependent phosphorylation of PDK1 at Ser504 and Ser532 contributes to palmitate-induced insulin resistance. J. Biol. Chem. 2009, 284, 2038–2044. [Google Scholar] [CrossRef]
  143. Sarma, P.; Kashyap, B.; Gurumayum, S.; Sarma, S.; Baruah, P.; Swargiary, D.; Saikia, A.; Deka, R.C.; Borah, J.C. Antihyperglycemic Potential of Quercetin-3-glucoside Isolated from Leucaena leucocephala Seedpods via the SIRT1/AMPK/GLUT4 Signaling Cascade. ACS Omega 2024, 9, 32429–32443. [Google Scholar] [CrossRef] [PubMed]
  144. Yoon, H.J.; Bang, M.-H.; Kim, H.; Imm, J.-Y. Improvement of palmitate-induced insulin resistance in C2C12 skeletal muscle cells using Platycodon grandiflorum seed extracts. Food Biosci. 2018, 25, 61–67. [Google Scholar] [CrossRef]
  145. Hsieh, C.T.; Chuang, J.H.; Yang, W.C.; Yin, Y.; Lin, Y. Ceramide inhibits insulin-stimulated Akt phosphorylation through activation of Rheb/mTORC1/S6K signaling in skeletal muscle. Cell. Signal 2014, 26, 1400–1408. [Google Scholar] [CrossRef]
  146. Bandet, C.L.; Tan-Chen, S.; Ali-Berrada, S.; Campana, M.; Poirier, M.; Blachnio-Zabielska, A.; Pais-de-Barros, J.P.; Rouch, C.; Ferré, P.; Foufelle, F.; et al. Ceramide analog C2-cer induces a loss in insulin sensitivity in muscle cells through the salvage/recycling pathway. J. Biol. Chem. 2023, 299, 104815. [Google Scholar] [CrossRef]
  147. Lin, C.H.; Kuo, Y.H.; Shih, C.C. Eburicoic Acid, a Triterpenoid Compound from Antrodia camphorata, Displays Antidiabetic and Antihyperlipidemic Effects in Palmitate-Treated C2C12 Myotubes and in High-Fat Diet-Fed Mice. Int. J. Mol. Sci. 2017, 18, 2314. [Google Scholar] [CrossRef] [PubMed]
  148. Feraco, A.; Gorini, S.; Mammi, C.; Lombardo, M.; Armani, A.; Caprio, M. Neutral Effect of Skeletal Muscle Mineralocorticoid Receptor on Glucose Metabolism in Mice. Int. J. Mol. Sci. 2023, 24, 7412. [Google Scholar] [CrossRef]
  149. Mazibuko-Mbeje, S.E.; Mthembu, S.X.; Muller, C.J.; Ziqubu, K.; Muvhulawa, N.; Modibedi, R.V.; Tiano, L.; Dludla, P.V. Aspalathin alleviates skeletal muscle insulin resistance and mitochondrial dysfunction. Physiol. Res. 2022, 71, 643–656. [Google Scholar] [CrossRef]
  150. Chen, Y.; Zhang, J.; Li, P.; Liu, C.; Li, L. N1-methylnicotinamide ameliorates insulin resistance in skeletal muscle of type 2 diabetic mice by activating the SIRT1/PGC-1α signaling pathway. Mol. Med. Rep. 2021, 23, 270. [Google Scholar] [CrossRef]
  151. Zhang, M.; Zhang, Y.; Huang, Q.; Duan, H.; Zhao, G.; Liu, L.; Li, Y. Flavonoids from Sophora alopecuroides L. improve palmitate-induced insulin resistance by inhibiting PTP1B activity in vitro. Bioorganic Med. Chem. Lett. 2021, 35, 127775. [Google Scholar] [CrossRef]
  152. Bitsi, S. The chemokine CXCL16 can rescue the defects in insulin signaling and sensitivity caused by palmitate in C2C12 myotubes. Cytokine 2020, 133, 155154. [Google Scholar] [CrossRef] [PubMed]
  153. de Mendonça, M.; de Sousa, É.; da Paixão, A.O.; Santos, B.A.D.; Spagnol, A.R.; Murata, G.M.; Araújo, H.N.; de Lima, T.I.; Guimarães, D.S.P.S.F.; Silveira, L.R.; et al. MicroRNA miR-222 mediates pioglitazone beneficial effects on skeletal muscle of diet-induced obese mice. Mol. Cell. Endocrinol. 2020, 501, 110661. [Google Scholar] [CrossRef]
  154. Huang, S.; Ma, S.; Ning, M.; Yang, W.; Ye, Y.; Zhang, L.; Shen, J.; Leng, Y. TGR5 agonist ameliorates insulin resistance in the skeletal muscles and improves glucose homeostasis in diabetic mice. Metabolism 2019, 99, 45–56. [Google Scholar] [CrossRef]
  155. Ayeleso, T.B.; Ramachela, K.; Mukwevho, E. Aqueous-Methanol Extracts of Orange-Fleshed Sweet Potato (Ipomoea batatas) Ameliorate Oxidative Stress and Modulate Type 2 Diabetes Associated Genes in Insulin Resistant C2C12 Cells. Molecules 2018, 23, 2058. [Google Scholar] [CrossRef]
  156. Xu, Q.; Luo, J.; Wu, N.; Zhang, R.; Shi, D. BPN, a marine-derived PTP1B inhibitor, activates insulin signaling and improves insulin resistance in C2C12 myotubes. Int. J. Biol. Macromol. 2018, 106, 379–386. [Google Scholar] [CrossRef] [PubMed]
  157. Zhou, Q.; Gu, Y.; Lang, H.; Wang, X.; Chen, K.; Gong, X.; Zhou, M.; Ran, L.; Zhu, J.; Mi, M. Dihydromyricetin prevents obesity-induced slow-twitch-fiber reduction partially via FLCN/FNIP1/AMPK pathway. Biochim. Biophys. Acta Mol. Basis Dis. 2017, 1863, 1282–1291. [Google Scholar] [CrossRef] [PubMed]
  158. Zhu, R.; Zheng, J.; Chen, L.; Gu, B.; Huang, S. Astragaloside IV facilitates glucose transport in C2C12 myotubes through the IRS1/AKT pathway and suppresses the palmitate-induced activation of the IKK/IκBα pathway. Int. J. Mol. Med. 2016, 37, 1697–1705. [Google Scholar] [CrossRef]
  159. Haghani, K.; Pashaei, S.; Vakili, S.; Taheripak, G.; Bakhtiyari, S. TNF-α knockdown alleviates palmitate-induced insulin resistance in C2C12 skeletal muscle cells. Biochem. Biophys. Res. Commun. 2015, 460, 977–982. [Google Scholar] [CrossRef]
  160. Li, H.B.; Yang, Y.R.; Mo, Z.J.; Ding, Y.; Jiang, W.J. Silibinin improves palmitate-induced insulin resistance in C2C12 myotubes by attenuating IRS-1/PI3K/Akt pathway inhibition. Braz. J. Med. Biol. Res. 2015, 48, 440–446. [Google Scholar] [CrossRef]
  161. Chen, P.Y.; Wang, J.; Lin, Y.C.; Li, C.C.; Tsai, C.W.; Liu, T.C.; Chen, H.W.; Huang, C.S.; Lii, C.K.; Liu, K.L. 18-carbon polyunsaturated fatty acids ameliorate palmitate-induced inflammation and insulin resistance in mouse C2C12 myotubes. J. Nutr. Biochem. 2015, 26, 521–531. [Google Scholar] [CrossRef] [PubMed]
  162. Mahfouz, R.; Khoury, R.; Blachnio-Zabielska, A.; Turban, S.; Loiseau, N.; Lipina, C.; Stretton, C.; Bourron, O.; Ferré, P.; Foufelle, F.; et al. Characterising the inhibitory actions of ceramide upon insulin signaling in different skeletal muscle cell models: A mechanistic insight. PLoS ONE 2014, 9, e101865. [Google Scholar] [CrossRef]
  163. Fabre, O.; Breuker, C.; Amouzou, C.; Salehzada, T.; Kitzmann, M.; Mercier, J.; Bisbal, C. Defects in TLR3 expression and RNase L activation lead to decreased MnSOD expression and insulin resistance in muscle cells of obese people. Cell Death Dis. 2014, 5, e1136. [Google Scholar] [CrossRef]
  164. Mazibuko, S.E.; Muller, C.J.; Joubert, E.; de Beer, D.; Johnson, R.; Opoku, A.R.; Louw, J. Amelioration of palmitate-induced insulin resistance in C2C12 muscle cells by rooibos (Aspalathus linearis). Phytomedicine 2013, 20, 813–819. [Google Scholar] [CrossRef]
  165. Peterson, J.M.; Wang, Y.; Bryner, R.W.; Williamson, D.L.; Alway, S.E. Bax signaling regulates palmitate-mediated apoptosis in C2C12 myotubes. Am. J. Physiol. Endocrinol. Metab. 2008, 295, E1307–E1314. [Google Scholar] [CrossRef]
  166. Chavez, J.A.; Summers, S.A. Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. Arch. Biochem. Biophys. 2003, 419, 101–109. [Google Scholar] [CrossRef] [PubMed]
  167. Jové, M.; Planavila, A.; Sánchez, R.M.; Merlos, M.; Laguna, J.C.; Vázquez-Carrera, M. Palmitate induces tumor necrosis factor-α expression in C2C12 skeletal muscle cells by a mechanism involving protein kinase C and nuclear factor-κB activation. Endocrinology 2006, 147, 552–561. [Google Scholar] [CrossRef]
  168. Aguer, C.; McCoin, C.S.; Knotts, T.A.; Thrush, A.B.; Ono-Moore, K.; McPherson, R.; Dent, R.; Hwang, D.H.; Adams, S.H.; Harper, M.E. Acylcarnitines: Potential implications for skeletal muscle insulin resistance. FASEB J. 2015, 29, 336–345. [Google Scholar] [CrossRef]
  169. Li, L.; Luo, Z.; Yu, H.; Feng, X.; Wang, P.; Chen, J.; Pu, Y.; Zhao, Y.; He, H.; Zhong, J.; et al. Telmisartan improves insulin resistance of skeletal muscle through peroxisome proliferator-activated receptor-δ activation. Diabetes 2013, 62, 762–774. [Google Scholar] [CrossRef]
  170. Chen, S.C.; Chen, P.Y.; Wu, Y.L.; Chen, C.W.; Chen, H.W.; Lii, C.K.; Sun, H.L.; Liu, K.L. Long-chain polyunsaturated fatty acids amend palmitate-induced inflammation and insulin resistance in mouse C2C12 myotubes. Food Funct. 2016, 7, 270–278. [Google Scholar] [CrossRef] [PubMed]
  171. Chen, J.; Zhu, J.; Meng, X. Aronia melanocarpa anthocyanin extracts are an effective regulator of suppressor of cytokine signaling 3-dependent insulin resistance in HepG2 and C2C12 cells. J. Funct. Foods 2020, 75, 104258. [Google Scholar] [CrossRef]
  172. Swargiary, D.; Kashyap, B.; Sarma, P.; Ahmed, S.A.; Gurumayum, S.; Barge, S.R.; Basumatary, D.; Borah, J.C. Free radical scavenging polyphenols isolated from Phyllanthus niruri L. ameliorates hyperglycemia via SIRT1 induction and GLUT4 translocation in in vitro and in vivo models. Fitoterapia 2024, 173, 105803. [Google Scholar] [CrossRef] [PubMed]
  173. Zhang, W.; Dun, Y.; You, B.; Qiu, L.; Ripley-Gonzalez, J.W.; Cheng, J.; Fu, S.; Li, C.; Liu, S. Trimetazidine and exercise offer analogous improvements to the skeletal muscle insulin resistance of mice through Nrf2 signaling. BMJ Open Diabetes Res. Care 2022, 10, e002699. [Google Scholar] [CrossRef] [PubMed]
  174. Wang, P.; Li, C.G.; Zhou, X.; Ding, S. Transcription factor EB enhances autophagy and ameliorates palmitate-induced insulin resistance at least partly via upregulating AMPK activity in skeletal muscle cells. Clin. Exp. Pharmacol. Physiol. 2022, 49, 302–310. [Google Scholar] [CrossRef]
  175. Han, M.; You, L.; Wu, Y.; Gu, N.; Wang, Y.; Feng, X.; Xiang, L.; Chen, Y.; Zeng, Y.; Zhong, T. RNA-sequencing analysis reveals the potential contribution of lncRNAs in palmitic acid-induced insulin resistance of skeletal muscle cells. Biosci. Rep. 2020, 40, BSR20192523. [Google Scholar] [CrossRef]
  176. Abu Bakar, M.H.; Tan, J.S. Improvement of mitochondrial function by celastrol in palmitate-treated C2C12 myotubes via activation of PI3K-Akt signaling pathway. Biomed. Pharmacother. 2017, 93, 903–912. [Google Scholar] [CrossRef]
  177. Kwak, H.J.; Choi, H.E.; Cheon, H.G. 5-LO inhibition ameliorates palmitic acid-induced ER stress, oxidative stress and insulin resistance via AMPK activation in murine myotubes. Sci. Rep. 2017, 7, 5025. [Google Scholar] [CrossRef]
  178. Li, H.; Liu, S.; Yuan, H.; Niu, Y.; Fu, L. Sestrin 2 induces autophagy and attenuates insulin resistance by regulating AMPK signaling in C2C12 myotubes. Exp. Cell Res. 2017, 354, 18–24. [Google Scholar] [CrossRef] [PubMed]
  179. Kwak, H.J.; Choi, H.E.; Jang, J.; Park, S.K.; Bae, Y.A.; Cheon, H.G. Bortezomib attenuates palmitic acid-induced ER stress, inflammation and insulin resistance in myotubes via AMPK dependent mechanism. Cell. Signal 2016, 28, 788–797. [Google Scholar] [CrossRef]
  180. Meshkani, R.; Sadeghi, A.; Taheripak, G.; Zarghooni, M.; Gerayesh-Nejad, S.; Bakhtiyari, S. Rosiglitazone, a PPARγ agonist, ameliorates palmitate-induced insulin resistance and apoptosis in skeletal muscle cells. Cell Biochem. Funct. 2014, 32, 683–691. [Google Scholar] [CrossRef] [PubMed]
  181. Dymkowska, D.; Drabarek, B.; Jakubczyk, J.; Wojciechowska, S.; Zabłocki, K. Potassium channel openers prevent palmitate-induced insulin resistance in C2C12 myotubes. Arch. Biochem. Biophys. 2014, 541, 47–52. [Google Scholar] [CrossRef] [PubMed]
  182. Senn, J.J. Toll-like receptor-2 is essential for the development of palmitate-induced insulin resistance in myotubes. J. Biol. Chem. 2006, 281, 26865–26875. [Google Scholar] [CrossRef] [PubMed]
  183. Yu, Y.; Yang, J.; Zheng, L.; Su, H.; Cao, S.; Jiang, X.; Liu, X.; Liu, W.; Wang, Z.; Meng, F.; et al. Dysfunction of Akt/FoxO3a/Atg7 regulatory loop magnifies obesity-regulated muscular mass decline. Mol. Metab. 2024, 81, 101892. [Google Scholar] [CrossRef]
  184. D’Souza, K.; Nzirorera, C.; Cowie, A.M.; Varghese, G.P.; Trivedi, P.; Eichmann, T.O.; Biswas, D.; Touaibia, M.; Morris, A.J.; Aidinis, V.; et al. Autotaxin-LPA signaling contributes to obesity-induced insulin resistance in muscle and impairs mitochondrial metabolism. J. Lipid Res. 2018, 59, 1805–1817. [Google Scholar] [CrossRef]
  185. Liu, X.; Yuan, H.; Niu, Y.; Niu, W.; Fu, L. The role of AMPK/mTOR/S6K1 signaling axis in mediating the physiological process of exercise-induced insulin sensitization in skeletal muscle of C57BL/6 mice. Biochim. Biophys. Acta 2012, 1822, 1716–1726. [Google Scholar] [CrossRef] [PubMed]
  186. Kadotani, A.; Tsuchiya, Y.; Hatakeyama, H.; Katagiri, H.; Kanzaki, M. Different impacts of saturated and unsaturated free fatty acids on COX-2 expression in C2C12 myotubes. Am. J. Physiol. Endocrinol. Metab. 2009, 297, E1291–E1303. [Google Scholar] [CrossRef] [PubMed][Green Version]
  187. Ragheb, R.; Shanab, G.M.; Medhat, A.M.; Seoudi, D.M.; Adeli, K.; Fantus, I.G. Free fatty acid-induced muscle insulin resistance and glucose uptake dysfunction: Evidence for PKC activation and oxidative stress-activated signaling pathways. Biochem. Biophys. Res. Commun. 2009, 389, 211–216. [Google Scholar] [CrossRef]
  188. Tsuchiya, Y.; Hatakeyama, H.; Emoto, N.; Wagatsuma, F.; Matsushita, S.; Kanzaki, M. Palmitate-induced down-regulation of sortilin and impaired GLUT4 trafficking in C2C12 myotubes. J. Biol. Chem. 2010, 285, 34371–34381. [Google Scholar] [CrossRef]
  189. Kusudo, T.; Kontani, Y.; Kataoka, N.; Ando, F.; Shimokata, H.; Yamashita, H. Fatty acid-binding protein 3 stimulates glucose uptake by facilitating AS160 phosphorylation in mouse muscle cells. Genes Cells 2011, 16, 681–691. [Google Scholar] [CrossRef]
  190. Pierre, N.; Fernández-Verdejo, R.; Regnier, P.; Vanmechelen, S.; Demeulder, B.; Francaux, M. IRE1α and TRB3 do not contribute to the disruption of proximal insulin signaling caused by palmitate in C2C12 myotubes. Cell Biol. Int. 2016, 40, 91–99. [Google Scholar] [CrossRef]
  191. Vong, S.-K.; Chen, C.-M.; Das, A.; Shyur, L.-F.; Ju, Y.-M.; Hsieh, H.-M.; Yang, S.-H.; Varga, V.; Li, S.-C. Stimulation of glucose uptake by edible Pholiota nameko (T.Itô) S.Ito & S.Imai extract counteracts palmitate-induced insulin resistance in C2C12 myotubes. Front. Sustain. Food Syst. 2025, 9, 1520875. [Google Scholar]
  192. Kim, K.-S.; Choi, Y.K.; Kim, M.J.; Yun, C.-K.; Hwang, J.W.; Min, K.; Jung, S.Y.; Soo-kyung, K.; Cho, Y.-W.; Choi, Y.-S. Effect of Mitochondrial Transfer via Centrifugation on Insulin Resistance in C2C12 Cells. J. Endocrinol. Metab. 2024, 14, 207–212. [Google Scholar] [CrossRef]
  193. Xiang, J.; Qin, L.; Zhong, J.; Xia, N.; Liang, Y. GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway. Diabetes Metab. Syndr. Obes. 2023, 16, 2433–2446. [Google Scholar] [CrossRef] [PubMed]
  194. Kim, K.S.; Choi, Y.K.; Kim, M.J.; Hwang, J.W.; Min, K.; Jung, S.Y.; Kim, S.K.; Choi, Y.S.; Cho, Y.W. Umbilical Cord-Mesenchymal Stem Cell-Conditioned Medium Improves Insulin Resistance in C2C12 Cell. Diabetes Metab. J. 2021, 45, 260–269. [Google Scholar] [CrossRef]
  195. Sun, Y.N.; Yang, Z.X.; Ren, F.Z.; Fang, B. FGF19 alleviates palmitate-induced atrophy in C2C12 cells by inhibiting mitochondrial overload and insulin resistance. Int. J. Biol. Macromol. 2020, 158, 401–407. [Google Scholar] [CrossRef]
  196. Zhou, Q.G.; Hou, F.F.; Guo, Z.J.; Liang, M.; Wang, G.B.; Zhang, X. 1,25-Dihydroxyvitamin D improved the free fatty-acid-induced insulin resistance in cultured C2C12 cells. Diabetes Metab. Res. Rev. 2008, 24, 459–464. [Google Scholar] [CrossRef]
  197. James, D.E.; Stöckli, J.; Birnbaum, M.J. The aetiology and molecular landscape of insulin resistance. Nat. Rev. Mol. Cell. Biol. 2021, 22, 751–771. [Google Scholar] [CrossRef] [PubMed]
Nutrients 17 03619 g001
Figure 1. Mechanistic overview of palmitate-induced insulin resistance. Notes: Solid black arrows denote signaling and activation. Arrows that travel behind a molecular target indicate that the molecular target over the arrow phosphorylates the target from which arrow originates. Green arrows indicate normal insulin signaling mechanisms. Red arrows indicate the contribution of this pathway negatively impacts insulin signaling. Dashed arrows indicate the uptake of palmitate or translocation of GLUT4 vesicles. Abbreviations: GLUT4, glucose transporter member 4; GSV, GLUT4 storage vesicles; Iκκ, I kappa B kinase; IRS1, insulin receptor substrate 1; IR, insulin receptor; PI3K, phosphatidylinositol 3-kinase; PKC, protein kinase c; ROS, reactive oxygen species; TLR4, toll-like receptor 4.
Figure 1. Mechanistic overview of palmitate-induced insulin resistance. Notes: Solid black arrows denote signaling and activation. Arrows that travel behind a molecular target indicate that the molecular target over the arrow phosphorylates the target from which arrow originates. Green arrows indicate normal insulin signaling mechanisms. Red arrows indicate the contribution of this pathway negatively impacts insulin signaling. Dashed arrows indicate the uptake of palmitate or translocation of GLUT4 vesicles. Abbreviations: GLUT4, glucose transporter member 4; GSV, GLUT4 storage vesicles; Iκκ, I kappa B kinase; IRS1, insulin receptor substrate 1; IR, insulin receptor; PI3K, phosphatidylinositol 3-kinase; PKC, protein kinase c; ROS, reactive oxygen species; TLR4, toll-like receptor 4.
Nutrients 17 03619 g001
Nutrients 17 03619 g002
Figure 2. Flowchart of search strategy and results from PubMed and Scopus search. Search strategy for palmitate-mediated insulin resistance in C2C12 myotubes using “C2C12 AND palmitate AND insulin resistance” with and without targets related to insulin resistance as outlined in Methods and figure above.
Figure 2. Flowchart of search strategy and results from PubMed and Scopus search. Search strategy for palmitate-mediated insulin resistance in C2C12 myotubes using “C2C12 AND palmitate AND insulin resistance” with and without targets related to insulin resistance as outlined in Methods and figure above.
Nutrients 17 03619 g002
Table 1. Findings from systematic search results on the effect of pharmacokinetically attainable levels of palmitate treatment at various concentrations for various durations on common indicators of insulin sensitivity.
Table 1. Findings from systematic search results on the effect of pharmacokinetically attainable levels of palmitate treatment at various concentrations for various durations on common indicators of insulin sensitivity.
Palmitate ConcentrationDurationVehicleInsulin StimulationInsulin Receptor Substrate
(pIRS)		Protein Kinase B
(pAkt)		Glucose Transporter 4
(GLUT4)		Glucose UptakeReference
0.05 mM16 hBSA17.2 nM × 15 min ↓ (≈24.6 ± 10%) De Wilde et al., 2010 [7]
0.0625 mM24 h BSANo ↓VC Cheon et al., 2014 [8]
0.0625 mM24 h BSA100 nM × 30 min ↓VC Cheon et al., 2014 [8]
0.075 mM24 hBSANo ↓ (≈39.1 ± 10%) ↓ (≈52.5 ± 10%)Huang et al., 2024 [9]
0.1 mM12 hBSAUnknown ↔ VC Chen et al., 2016 [10]
0.1 mM16 hBSA17.2 nM × 15 min ↓ (≈32.0 ± 10%) De Wilde et al., 2010 [7]
0.1 mM16 hBSA100 nM × 10 min ↓ VC Chavez et al., 2005 [11]
0.1 mM16 hBSANo ↔ (≈100.0 ± 5%) SEMNa et al., 2025 [12]
0.1 mM16 hBSA200 nM × 20 min ↓ (≈61.0 ± 5%) SEMNa et al., 2025 [12]
0.1 mM (3D)16 hBSANo ↔ (≈100.0 ± 5%) SEMNa et al., 2025 [12]
0.1 mM (3D)16 hBSA200 nM × 20 min ↓ (≈50.0 ± 5%) SEMNa et al., 2025 [12]
0.1 mM18 h BSANo ↓ (≈83.6 ± 5%)Park et al., 2014 [13]
0.1 mM18 h BSA100 nM × 10 min ↓ (≈61.4 ± 5%)Park et al., 2014 [13]
0.1 mM24 hBSANo↓ (≈65.7 ± 5%) ↓ (≈60.5 ± 5%)↓ (≈60.0 ± 5%)Ren et al., 2025 [14]
0.1 mM24 hBSA10 nM × 30 min ↓ (≈85.7 ± 5%)↓ (≈84.0 ± 5%) Norouzi et al., 2019 [15]
0.1 mM24 hBSA100 nM × 30 min↔ (≈108.3 ± 5%)↔ (≈85.3 ± 5%)↔ (≈92.5 ± 5%)↔ (≈109.0 ± 5%)Pan et al., 2023 [16]
0.1 mM24 hBSANo↔ (≈72.7 ± 5%) ↔ (≈100.0 ± 5%) Zhang et al., 2018 [17]
0.1 mM24 hBSANo ↔ (≈95.0 ± 5%) Hirabara et al., 2010 [18]
0.1 mM24 hBSA7 nM × 30 min ↓ (≈51.0 ± 5%) Hirabara et al., 2010 [18]
0.1 mM24 hBSA100 nM × 30 min ↔ (≈93.0 ± 10%)↔ (≈96.0 ± 5%)Zhang et al., 2015 [19]
0.125 mM16 hBSANo ↔ (≈100.0 ± 5%) SEMFeng et al., 2012 [20]
0.125 mM16 hBSA100 nM × 30 min ↔ (≈91.6 ± 5%) SEMFeng et al., 2012 [20]
0.125 mM 24 h BSANo ↓ VC ↓ (≈71.8 ± 5%) SEMCheon et al., 2014 [8]
0.125 mM 24 h BSA100 nM × 30 min ↓ VC ↓ (≈67.0 ± 5%) SEMCheon et al., 2014 [8]
0.15 mM16 hBSANo ↔ (≈100.0 ± 5%) SEMNa et al., 2025 [12]
0.15 mM16 hBSA200 nM × 20 min ↓ (≈61.0 ± 5%) SEMNa et al., 2025 [12]
0.15 mM (3D)16 hBSANo ↔ (≈100.0 ± 5%) SEMNa et al., 2025 [12]
0.15 mM (3D)16 hBSA200 nM × 20 min ↓ (≈35.7 ± 5%) SEMNa et al., 2025 [12]
0.15 mM (LG)24 hBSANo ↔ (≈86.2 ± 5%)Kopp et al., 2023 [21]
0.15 mM (LG)24 hBSA100 nM × 20 min ↔ (≈84.6 ± 5%)Kopp et al., 2023 [21]
0.15 mM (HG)24 hBSANo ↓ (≈68.8 ± 5%)Kopp et al., 2023 [21]
0.15 mM (HG)24 hBSA100 nM × 20 min ↓ (≈82.8 ± 5%)Kopp et al., 2023 [21]
0.15 mM (LG)96 hBSANo ↔ (≈113.6 ± 5%)Kopp et al., 2023 [21]
0.15 mM (LG)96 hBSA100 nM × 20 min ↔ (≈87.9 ± 5%)Kopp et al., 2023 [21]
0.15 mM (HG)96 hBSANo ↓ (≈67.2 ± 5%)Kopp et al., 2023 [21]
0.15 mM (HG)96 hBSA100 nM × 20 min ↓ (≈77.4 ± 5%)Kopp et al., 2023 [21]
0.2 mM8 hBSANo ↔ (≈94.4 ± 5%)↔ (≈30.7 ± 5%) Mok et al., 2020 [22]
0.2 mM8 hBSA100 nM × 60 min ↓ (≈49.3 ± 5%)↓ (≈44.8 ± 5%) Mok et al., 2020 [22]
0.2 mM12 hBSAUnknown ↓ VC Chen et al., 2016 [10]
0.2 mM16 hBSANo ↔ (≈100.0 ± 5%) SEMNa et al., 2025 [12]
0.2 mM16 hBSA200 nM × 20 min ↓ (≈55.9 ± 5%) SEMNa et al., 2025 [12]
0.2 mM (3D)16 hBSANo ↔ (≈118.2 ± 5%) SEMNa et al., 2025 [12]
0.2 mM (3D)16 hBSA200 nM × 20 min ↓ (≈35.7 ± 5%) SEMNa et al., 2025 [12]
0.2 mM 16 h BSANo ↔ (≈55.6 ± 5%) SEM ↓ (≈78.9 ± 5%) SEMLiu et al., 2015 [23]
0.2 mM 16 h BSA200 nM × 30 min ↓ (≈21.8 ± 5%) SEM ↓ (≈70.4 ± 5%) SEMLiu et al., 2015 [23]
0.2 mM 16 h BSA100 nM × 120 min ↓VC Kirk-Ballard et al., 2014 [24]
0.2 mM16 hBSA50 nM × 15 min ↓ (≈7.8 ± 5%) Gone et al., 2024 [25]
0.2 mM16 hBSA17.2 nM × 15 min ↓ (≈17.5 ± 5%) De Wilde et al., 2010 [7]
0.2 mM16 hNR10 nM × 30 min ↓ (≈44.2 ± 5%) SEMJheng et al., 2012 [26]
0.2 mM16 hEtOHNo ↔ (≈97.1 ± 5%)Parvaneh et al., 2010 [27]
0.2 mM16 hEtOH100 nM × 30 min ↔ (≈100.0 ± 5%)Parvaneh et al., 2010 [27]
0.2 mM19 hBSA10 nM × 10 min ↓ VC Blackburn et al., 2020 [28]
0.2 mM19 hBSA100 nM × 10 min ↓ VC Blackburn et al., 2020 [28]
0.2 mM 24 h BSANo ↔ (≈103.4 ± 5%)Tatebe et al., 2011 [29]
0.2 mM 24 h BSA100 nM × 10 min ↔ (≈88.4 ± 5%)↔ (≈105.9 ± 5%)↔ (≈100.0 ± 5%)Tatebe et al., 2011 [29]
0.2 mM24 hBSA10 nM × 30 min ↓ (≈22.8 ± 5%) ↓ (≈56.8 ± 5%) Norouzi et al., 2019 [15]
0.2 mM24 hBSA10 nM × 3 min↓ (≈21.0 ± 5%)↓ (≈10.5 ± 5%) ↓ (≈47.7 ± 5%)Gwon et al., 2024 [30]
0.2 mM24 hBSANo ↔ (≈96.9 ± 5%) Wu et al., 2024 [31]
0.2 mM24 hBSAYes, unknown conditions ↓ (≈59.6 ± 5%) ↓ (≈73.6 ± 5%)Wu et al., 2024 [31]
0.2 mM24 hBSA50 nM × 10 min↓ (≈45.7 ± 5%)↓ (≈57.1 ± 5%) ↓ (≈43.5 ± 5%)Sun et al., 2024 [32]
0.2 mM24 hBSA100 nM × 10 min ↓ (≈47.7 ± 5%) SEM ↓ (≈66.2 ± 5%) SEMLi et al., 2023 [33]
0.2 mM24 hBSA10 nM × 3 min↓ (≈20.9 ± 5%)↓ (≈27.1 ± 5%) ↓ (≈43.6 ± 5%)Oh et al., 2022 [34]
0.2 mM24 hBSA10 nM × 3 min↓ (≈38.0 ± 5%) SEM↓ (≈17.5 ± 5%) SEM ↓ (≈42.1 ± 5%) SEMJung et al., 2022 [35]
0.2 mM24 hBSA10 nM × 3 min↓ (≈30.6 ± 10%) SEM↓ (≈26.5 ± 10%) SEM ↓ (≈52.5 ± 5%) SEMPark et al., 2021 [36]
0.2 mM24 hBSANo ↔ (≈72.7 ± 5%) Pesta et al., 2021 [37]
0.2 mM24 hBSA100 nM × 10 min ↓ (≈57.6 ± 5%) Pesta et al., 2021 [37]
0.2 mM24 hBSA10 nM × 3 min↓ (≈24.0 ± 5%) SEM↓ (≈38.8 ± 5%) SEM ↓ (≈40.3 ± 5%) SEMJung et al., 2021 [38]
0.2 mM24 hBSA10 nM × 3 min↓ (≈50.6 ± 5%) SEM↓ (≈23.3 ± 5%) SEM ↓ (≈44.2 ± 5%) SEMKim et al., 2021 [39]
0.2 mM24 hBSA100 nM × 30 min↓ (≈46.9 ± 5%)↓ (≈78.8 ± 5%) ↓ (≈69.3 ± 5%)Liu et al., 2020 [40]
0.2 mM24 hBSA100 nM × 10 min ↓ (≈81.9 ± 5%) Chiu et al., 2021 [41]
0.2 mM24 hBSA100 nM × 30 min↓ (≈45.0 ± 5%)↓ (≈36.4 ± 5%) ↓ (≈59.4 ± 5%)Chuang et al., 2020 [42]
0.2 mM24 hBSAUnknown × 15 min↓ (≈33.3 ± 5%) SEM↓ (≈52.4 ± 5%) Park et al., 2020 [43]
0.2 mM24 hBSA10 nM × 3 min↓ (≈43.8 ± 5%) SEM↓ (≈17.6 ± 5%) SEM ↓ (≈30.3 ± 5%) SEMSun et al., 2020 [44]
0.2 mM24 hBSA10 nM × 3 min↓ (≈6.0 ± 5%) SEM↓ (≈20.8 ± 5%) SEM ↓ (≈34.1 ± 5%) SEMJung et al., 2017 [45]
0.2 mM24 hBSAUnknown ↓ (≈76.8 ± 5%) SEM↓ (≈57.7 ± 5%) SEM↓ (≈51.9 ± 5%) SEMKulabas et al., 2018 [46]
0.2 mM24 hBSA100 nM × 15 min ↓ VC↔ (≈57.5 ± 5%) SEM↓ (≈85.1 ± 5%) SEMYang et al., 2013 [47]
0.2 mM24 hBSA10 nM × 3 min↓ (≈48.8 ± 5%) SEM↓ (≈33.3 ± 5%) SEM Jung et al., 2015 [48]
0.2 mM24 hBSA10 nM × 3 min↓ (≈75.8 ± 5%) SEM↓ (≈68.0 ± 5%) SEM ↓ (≈42.3 ± 5%) SEMJung et al., 2017 [49]
0.2 mM24 hBSANo ↔ (≈141.3 ± 5%) SEMZhang et al., 2015 [19]
0.2 mM24 hBSA100 nM × 30 min ↓ (≈60.4 ± 5%)↓ (≈82.3 ± 5%)Zhang et al., 2015 [19]
0.2 mM24 hBSANo ↓ (≈46.1 ± 5%) SEM Yang et al., 2012 [50]
0.2 mM48 hBSA10 nM × 3 min↓ (≈24.3 ± 5%) SEM↓ (≈19.5 ± 5%) SEM ↓ (≈40.9 ± 5%) SEMPyun et al., 2021 [51]
0.2 mM24 hBSA100 nM × 30 min ↓ (≈58.8 ± 5%) SEM Yang et al., 2012 [50]
0.2 mM48 hBSA10 nM × 3 min↓ (≈24.3 ± 5%)↓ (≈18.3 ± 5%) ↓ (≈41.0 ± 5%)Jung et al., 2020 [52]
0.2 mM48 hBSANo ↔ VC ↔ (≈104.1 ± 5%)de Figueiredo et al., 2015 [53]
0.2 mM48 hBSA100 nM × 30 min ↓ (≈50.0 ± 5%) ↓ (≈67.3 ± 5%)de Figueiredo et al., 2015 [53]
0.25 mM12 hBSA100 nM × 30 min ↔ (≈95.3 ± 5%)Zhao et al., 2012 [54]
0.25 mM16 hBSA100 nM × 30 min ↓ (≈46.6 ± 5%) Kim et al., 2022 [55]
0.25 mM16 hBSA20 nM × 60 min (with amino acids) ↓ (≈48.4 ± 5%) SEM Cruz et al., 2020 [56]
0.25 mM16 hBSANo ↔ (≈100.0 ± 5%) SEM Bosquet et al., 2018 [57]
0.25 mM16 hBSA100 nM × 10 min ↓ (≈50.4 ± 5%) SEM Bosquet et al., 2018 [57]
0.25 mM16 hUnconjugated100 nM × 30 min ↔ (≈100.0 ± 5%) SEMLee et al., 2017 [58]
0.25 mM16 hBSA100 nM × 30 min ↔ (≈78.4 ± 5%) SEMLee et al., 2017 [58]
0.25 mM16 hBSANo ↓ (≈74.0 ± 5%) SEM Zhou et al., 2007 [59]
0.25 mM16 hBSA100 nM × 10 min ↓ (≈50.0 ± 5%) SEM Hage Hassan et al., 2012 [60]
0.25 mM16 hBSANo ↔ (≈96.8 ± 5%)Zhang et al., 2010 [61]
0.25 mM16 hBSA100 nM × 20 min ↔ (≈96.0 ± 5%)Zhang et al., 2010 [61]
0.25 mM16 hBSA100 nM × 10 min ↓ VC Chavez et al., 2005 [11]
0.25 mM16 hBSANo ↔ (≈100.0 ± 5%) SEMFeng et al., 2012 [20]
0.25 mM16 hBSA100 nM × 30 min ↓ (≈87.4 ± 5%) SEMFeng et al., 2012 [20]
0.25 mM 18 h BSA No ↓ (≈61.8 ± 5%)Park et al., 2014 [13]
0.25 mM 18 h BSA 100 nM × 10 min ↓ (≈57.8 ± 5%)
 ↓ (≈42.7 ± 5%)Park et al., 2014 [13]
0.25 mM18 hBSA100 nM × 30 min ↔ VC ↓ (≈65.1 ± 5%) SEMQin et al., 2009 [62]
0.25 mM 24 h BSA No ↓ VC ↓ (≈65.6 ± 5%) SEMCheon et al., 2014 [8]
0.25 mM 24 h BSA 100 nM × 30 min ↓ VC ↓ (≈54.8 ± 5%) SEMCheon et al., 2014 [8]
0.25 mM 24 h BSA ↓ (≈61.2 ± 5%) SEM Chang et al., 2018 [63]
0.25 mM24 hBSA100 nM × 30 min↔ (≈112.5 ± 5%)↔ (≈78.0 ± 5%)↔ (≈85.0 ± 5%)↔ (≈113.6 ± 5%)Pan et al., 2023 [16]
0.25 mM24 hBSA100 nM × 30 min↔ (≈94.7 ± 5%) SEM↓ (≈90.5 ± 5%) SEM ↓ VCLi et al., 2023 [64]
0.25 mM24 hBSA100 nM × 30 min ↓ (≈55.9 ± 5%) SEM↓ (≈68.8 ± 5%) SEM↓ (≈72.7 ± 5%) SEMYu et al., 2022 [65]
0.25 mM24 hBSANo ↓ (≈50.0 ± 5%) SEMJiao et al., 2022 [66]
0.25 mM24 hBSA100 nM × unknown ↓ (≈38.6 ± 5%) SEMJiao et al., 2022 [66]
0.25 mM24 hBSANo ↓ (≈54.5 ± 5%) He et al., 2022 [67]
0.25 mM24 hBSA100 nM × 60 min ↓ (≈47.8 ± 5%) SEMHu et al., 2022 [68]
0.25 mM24 hBSANo ↔ (≈100.0 ± 5%) Nan et al., 2021 [69]
0.25 mM24 hBSA100 nM × 30 min ↓ (≈45.7 ± 5%) Nan et al., 2021 [69]
0.25 mM24 hBSANo↓ (≈32.2 ± 5%)↔ (≈70.9 ± 5%) Shen et al., 2019 [70]
0.25 mM24 hBSA100 nM × 30 min↓ (≈27.2 ± 5%)↓ (≈30.3 ± 5%) ↓ (≈51.4 ± 5%)Shen et al., 2019 [70]
0.25 mM24 hBSA100 nM × 30 min ↓ (≈60.4 ± 5%)↓ (≈55.3 ± 5%)↓ VCZhang et al., 2019 [71]
0.25 mM24 hBSANo ↔ (≈109.0 ± 5%)Fujiwara et al., 2017 [72]
0.25 mM24 hBSA100 nM × 20 min ↓ (≈47.2 ± 5%)Fujiwara et al., 2017 [72]
NOTES: NR indicates detail was not reported. VC indicates visual confirmation was used and statistical comparisons were not made for relevant groups or only used single image densitometry. Abbreviations: bovine serum albumin (BSA), ethanol (EtOH), low glucose (LG), high glucose (HG). ↓: indicates a reported decrease in the target versus control; ↔: indicates no difference reported in the target versus control.
Table 2. Findings from systematic search results on the effect of moderately greater than pharmacokinetically attainable levels of palmitate treatment at various concentrations for various durations on common indicators of insulin sensitivity.
Table 2. Findings from systematic search results on the effect of moderately greater than pharmacokinetically attainable levels of palmitate treatment at various concentrations for various durations on common indicators of insulin sensitivity.
Palmitate ConcentrationDurationVehicleInsulin StimulationInsulin Receptor Substrate
(pIRS)		Protein Kinase B
(pAkt)		Glucose Transporter 4
(GLUT4)		Glucose UptakeReference
0.3 mM12 hBSAUnknown ↓ VC Chen et al., 2016 [10]
0.3 mM16 hBSANo ↔ (≈75.0 ± 5%) SEM Lee et al., 2020 [73]
0.3 mM16 hBSA100 nM × 120 min ↓ (≈84.6 ± 5%) SEM Lee et al., 2020 [73]
0.3 mM16 hBSANo ↓ (≈38.4 ± 5%) SEMChien et al., 2020 [74]
0.3 mM 18 h BSA 100 nM × 15 min ↓ (≈61.7 ± 5%) Smimmo et al., 2025 [75]
0.3 mM 24 h BSA No ↓ (≈36.3 ± 5%) Yang et al., 2024 [76]
0.3 mM 24 h BSA No ↓ (≈46.9 ± 5%) ↓ (≈65.7 ± 5%) Mao et al., 2025 [77]
0.3 mM24 hBSA10 nM × 30 min ↓ (≈25.7 ± 5%) ↓ (≈36.3 ± 5%) Norouzi et al., 2019 [15]
0.3 mM24 h *BSA20 nM × 15 min ↓ (≈56.8 ± 5%) Kwon et al., 2015 [78]
0.35 mM18 hBSANo ↔ (≈92.8 ± 5%) SEM Chen et al., 2017 [79]
0.35 mM18 hBSA10 nM × 10 min ↓ (≈50.0 ± 5%) SEM ↓ (≈78.1 ± 5%) SEMChen et al., 2017 [79]
0.375 mM16 hBSA100 nM × 30 min ↓ (≈59.1 ± 5%) SEM Tardif et al., 2014 [80]
0.4 mM6 hBSANo ↔ (≈89.2 ± 5%)Dai et al., 2016 [81]
0.4 mM6 hBSA1 µM × 18 min ↓ (≈71.4 ± 5%)Dai et al., 2016 [81]
0.4 mM24 hBSA100 nM × 30 min ↓ (≈67.6 ± 5%) Dai et al., 2016 [81]
0.4 mM12 hBSAUnknown ↓ VC Chen et al., 2016 [10]
0.4 mM16 hBSANo ↔ (≈50.0 ± 5%) ↔ (≈79.2 ± 5%) SEMLee et al., 2020 [73]
0.4 mM16 hBSA100 nM × 120 min ↓ (≈66.1 ± 5%) SEM ↓ (≈66.6 ± 5%) SEMLee et al., 2020 [73]
0.4 mM16 hBSA17.2 nM × 15 min ↓ (≈15.2 ± 5%) De Wilde et al., 2010 [7]
0.4 mM18 hBSA100 nM × 15 min ↓ (≈53.0 ± 5%)↓ (≈63.6 ± 5%) D’Souza et al., 2020 [82]
0.4 mM 24 h BSANo ↓ (≈59.5 ± 5%)↓ (≈79.6 ± 5%)Zhang et al., 2024 [83]
0.4 mM 24 h BSA100 nM × 30 min ↓ (≈85.5 ± 5%)Zhang et al., 2024 [83]
0.4 mM 24 h BSANo ↔ (≈66.6 ± 5%) SEM Jakovljevic et al., 2021 [84]
0.4 mM 24 h BSA120 nM × 15 min ↓ (≈47.6 ± 5%) SEM Jakovljevic et al., 2021 [84]
0.4 mM24 hBSA100 nM × 10 min ↓ (≈58.3 ± 5%)↓ (≈51.6 ± 5%)Chiu et al., 2021 [41]
0.4 mM24 hBSA100 nM × 30 min↓ (≈38.5 ± 5%)↓ (≈68.8 ± 5%) ↓ (≈60.0 ± 5%)Liu et al., 2020 [40]
0.4 mM24 hBSA100 nM × 30 min ↓ VC↓ VCWu et al., 2018 [85]
0.4 mM24 hBSA100 nM × 15 min ↓ VC↓ (≈30.3 ± 5%) SEM↔ (≈75.5 ± 5%) SEMYang et al., 2013 [47]
0.4 mM24 hBSANo ↓ (≈30.7 ± 5%) SEM Yang et al., 2012 [50]
0.4 mM24 hBSA100 nM × 30 min ↓ (≈38.8 ± 5%) SEM Yang et al., 2012 [50]
0.4 mM 36 h BSANo (≈167.1 ± 5%) SEM Fan et al., 2021 [86]
0.5 mM0.5 hBSAUnknown ↔ VC Chen et al., 2016 [10]
0.5 mM1 hBSAUnknown ↔ VC Chen et al., 2016 [10]
0.5 mM2 hBSAUnknown ↔ VC Chen et al., 2016 [10]
0.5 mM4 hBSANo ↑ (≈50.0 ± 5%)Nieuwoudt et al., 2017 [87]
0.5 mM4 hBSA1 µM × 30 min ↓ (≈71.8 ± 5%)Nieuwoudt et al., 2017 [87]
0.5 mM4 hBSA1 µM × 10 min ↔ (≈114.8 ± 5%) Nieuwoudt et al., 2017 [87]
0.5 mM4 hBSAUnknown ↓ VC Chen et al., 2016 [10]
0.5 mM6 hBSANo ↑ (≈1060.0 ± 5%) ↔ (≈94.8 ± 5%)Kim et al., 2018 [88]
0.5 mM6 hBSA100 nM × 15 min ↓ (≈58.0 ± 5%) ↓ (≈73.4 ± 5%)Kim et al., 2018 [88]
0.5 mM6 hBSAUnknown ↓ VC Chen et al., 2016 [10]
0.5 mM8 hBSAUnknown ↓ VC Chen et al., 2016 [10]
0.5 mM10 hBSAUnknown ↓ VC Chen et al., 2016 [10]
0.5 mM12 hBSANo ↔ VC Chen et al., 2016 [10]
0.5 mM12 hBSAUnknown ↓ VC Chen et al., 2016 [10]
0.5 mM 12 h BSANo ↓ VC Li et al., 2011 [89]
0.5 mM 12 h BSA100 nM × 5 min ↓ VC Li et al., 2011 [89]
0.5 mM12 hBSANo↔ (100.0 ± 5%)↔ (100.0 ± 5%) Zhao et al., 2012 [54]
0.5 mM12 hBSA100 nM × 30 min↑ (≈356.5 ± 5%)↓ (≈52.9 ± 10%) ↓ (≈68.4 ± 5%)Zhao et al., 2012 [54]
0.5 mM16 hBSA100 nM × 60 min ↓ VC↓ (≈26.2 ± 5%) SEMZhou et al., 2014 [90]
0.5 mM16 hBSANo ↔ (≈100.0 ± 5%) SEM Paez et al., 2023 [91]
0.5 mM16 hBSA100 nM × 120 min ↓ (≈55.1 ± 5%) SEM Paez et al., 2023 [91]
0.5 mM16 hBSA100 nM × 30 min ↑ (110.0 ± 5%) SEM↓ (77.1 ± 5%) SEM ↓ (84.3 ± 5%) SEMJia et al., 2021 [92]
0.5 mM16 hBSA100 ng/mL × 15 min ↓ (≈36.2 ± 10%) Rustamov et al., 2024 [93]
0.5 mM16 hBSA20 nM × 60 min (with amino acids) ↓ (≈25.7 ± 5%) SEM Cruz et al., 2020 [56]
0.5 mM16 hBSA100 nM × 10 min ↓ (≈58.6 ± 5%) Pinel et al., 2018 [94]
0.5 mM16 hBSA1 µg/mL × 4 h ↓ (≈76.8 ± 5%) Pinel et al., 2018 [94]
0.5 mM16 hBSA100 nM × 10 min↑ (≈356.5 ± 5%)↓ (≈27.7 ± 5%) Aoki et al. [95]
0.5 mM16 hUnconjugated100 nM × 30 min ↔ (≈100.0 ± 5%) SEMBotteri et al., 2018 [96]
0.5 mM16 hBSA100 nM × 30 min ↓ (≈56.8 ± 5%) SEMLee et al., 2017 [58]
0.5 mM16 hBSANo↔ (≈125.0 ± 5%)↔ (≈66.6 ± 5%)↔ (≈90.0 ± 5%) Lee et al., 2017 [58]
0.5 mM16 hBSA100 nM × 10 min↑ (≈200.0 ± 5%)↓ (≈42.8 ± 5%)↓ (≈63.7 ± 5%) Li et al., 2018 [97]
0.5 mM16 hBSANo ↔ (≈83.3 ± 5%) Li et al., 2018 [97]
0.5 mM16 hBSAYes, unknown conditions ↓ (≈63.6 ± 5%) Qin et al., 2017 [98]
0.5 mM16 hBSA100 nM × 30 min↑ VC↓ VC ↓ (≈61.1 ± 5%) SEMQin et al., 2017 [98]
0.5 mM16 hBSA100 nM × 10 min ↓ (≈62.9 ± 5%) Lee et al., 2017 [58]
0.5 mM16 hBSA1 nM × 15 min ↓ VC Capel et al., 2016 [99]
0.5 mM16 hBSA100 nM × 15 min ↓ Thr308 (≈54.0 ± 5%) Capel et al., 2016 [99]
0.5 mM16 hBSA100 nM × 15 min ↓ Ser473 (≈60.0 ± 5%) ↓ (≈80.7 ± 5%)Park et al., 2016 [100]
0.5 mM16 hBSA100 nM × 10 min ↓ Thr308 (≈34.3 ± 5%) Pinel et al., 2015 [101]
0.5 mM16 hBSA100 nM × 10 min ↓ Ser473 (≈61.667 ± 5%) ↓ (≈56.0 ± 5%)Capel et al., 2015 [102]
0.5 mM16 hBSA100 nM × >10 min ↓ (≈75.0 ± 5%) ↓ (≈56.6 ± 5%)Salvado et al., 2013 [103]
0.5 mM16 hBSA100 nM × 30 min ↓ (≈32.2 ± 5%)↓ (≈51.5 ± 5%)Jing et al., 2017 [104]
0.5 mM16 hBSANo ↔ (≈86.2 ± 5%)Karimfar et al., 2015 [105]
0.5 mM16 hBSA100 nM × 30 min ↓ (≈51.0 ± 5%)Karimfar et al., 2015 [105]
0.5 mM16 hBSANo↑ (≈193.7 ± 5%) SEM↓ (≈80.0 ± 5%) SEM Zhou et al., 2007 [59]
0.5 mM16 hBSA100 nM × 10 min↓ (≈81.9 ± 5%)↓ (≈72.5 ± 5%) ↓ (≈75.6 ± 5%)Bakhtiyari et al. [106]
0.5 mM16 hBSANo ↔ (≈87.5 ± 5%)Zhang et al., 2010 [61]
0.5 mM16 hBSA100 nM × 20 min ↓ (≈85.3 ± 5%)Zhang et al., 2010 [61]
0.5 mM16 hBSANo ↓ (≈236.3 ± 5%)↔ (≈154.3 ± 5%)Jove et al., 2005 [107]
0.5 mM16 hBSA100 nM × 30 min ↓ (≈65.3 ± 5%)Jove et al., 2005 [107]
0.5 mM16 hBSANo ↔ (83.3 ± 5%) SEM Henique et al., 2010 [108]
0.5 mM16 hBSA100 nM × 10 min ↓ (49.1 ± 5%) SEM Henique et al., 2010 [108]
0.5 mM16 hBSANo↑ VC Coll et al., 2010 [109]
0.5 mM16 hBSA100 nM × 10 min ↓ (≈78.9 ± 5%) ↓ (≈61.3 ± 5%)Coll et al., 2010 [109]
0.5 mM *16 hBSANo ↓ (≈43.1 ± 5%) Zhou et al., 2007 [59]
0.5 mM16 hBSA100 nM × 10 min ↓ (≈79.5 ± 5%) SEM Hage Hassan et al., 2012 [60]
0.5 mM16 hBSANo ↔ (≈103.2 ± 5%) SEM ↔ (≈100.0 ± 5%) SEMFeng et al., 2012 [20]
0.5 mM16 hBSA100 nM × 30 min ↓ (≈60.4 ± 5%) SEM ↓ (≈80.0 ± 5%) SEMFeng et al., 2012 [20]
0.5 mM16 hBSANo ↔ (≈101.5 ± 5%) SEMFeng et al., 2012 [110]
0.5 mM16 hBSA100 nM × 20 min ↓ (≈82.8 ± 5%) SEMFeng et al., 2012 [110]
0.5 mM16 hBSANo ↔ (≈97.3 ± 5%) SEMGorgani-Firuzjaee et al., 2012 [111]
0.5 mM16 hBSA100 nM × 30 min ↓ (76.0 ± 5%) SEMGorgani-Firuzjaee et al., 2012 [111]
0.5 mM16 hBSA100 nM × 15 min↓ (≈70.4 ± 5%) SEM↓ (≈68.7 ± 5%) SEM Gorgani-Firuzjaee et al., 2012 [111]
0.5 mM 18 h BSANo ↓ (≈41.8 ± 5%)Park et al., 2014 [13]
0.5 mM 18 h BSA100 nM × 10 min ↓ (≈50.5 ± 5%) ↓ (≈23.9 ± 5%)Park et al., 2014 [13]
0.5 mM18 hBSA100 nM × 30 min ↓ (≈58.1 ± 5%)↓ (≈62.5 ± 5%)↓ (≈61.5 ± 5%)Li et al., 2024 [112]
0.5 mM18 hNo10 nM × 20 min ↓ (≈66.6 ± 5%) SEM Aswad et al., 2014 [113]
0.5 mM18 hBSA10 nM × 20 min ↓ (≈65.4 ± 5%) SEM Aswad et al., 2014 [113]
0.5 mM19 hBSA10 nM × 10 min ↓ VC Blackburn et al., 2020 [28]
0.5 mM19 hBSA100 nM × 10 min ↓ VC Blackburn et al., 2020 [28]
0.5 mM24 hEtOH100 nM × 30 min ↔ (≈91.0 ± 5%) ↔ (≈86.6 ± 5%)Rivera et al., 2021 [114]
0.5 mM24 hDMSONo↓ (≈83.8 ± 5%)↑ (≈134.4 ± 5%) ↓ (≈81.4 ± 5%)Wu et al., 2020 [115]
0.5 mM 24 h BSA 100 nM × 24 h ↓ (≈43.2 ± 5%)↓ (≈66.6 ± 5%) Song et al., 2024 [116]
0.5 mM 24 h BSA 100 nM × 15 min ↓VC↓VC↑ (≈231.5 ± 5%)Shree et al., 2016 [117]
0.5 mM 24 h BSA No ↓ (≈72.6 ± 5%)Li et al., 2022 [118]
0.5 mM 24 h BSA 1 µg/mL × 30 min ↓ (≈62.6 ± 5%)Li et al., 2022 [118]
0.5 mM 24 h BSA No ↓VC ↓ (≈67.1 ± 5%) SEMCheon et al., 2014 [8]
0.5 mM 24 h BSA 100 nM × 30 min ↓VC ↓ (≈52.4 ± 5%) SEMCheon et al., 2014 [8]
0.5 mM24 hBSANo ↔ (≈72.7 ± 5%) Silva et al., 2024 [119]
0.5 mM24 hBSA100 nM × 30 min ↓ (≈39.2 ± 5%) Silva et al., 2024 [119]
0.5 mM24 hBSANo ↓ VC Li et al., 2024 [120]
0.5 mM24 hBSA100 nM × 30 min ↓ (≈59.5 ± 5%) ↓ (≈34.9 ± 5%)Li et al., 2024 [120]
0.5 mM24 hBSA100 nM × 30 min↑ (≈204.1 ± 5%)↓ (≈46.3 ± 5%)↓ (≈30.0 ± 5%)↑ (≈140.9 ± 5%)Pan et al., 2023 [16]
0.5 mM24 hBSANo ↓ (≈91.5 ± 5%) SEMGuo et al., 2023 [121]
0.5 mM24 hBSA1 µM × 60 min ↓ (≈77.7 ± 5%) SEM Guo et al., 2023 [121]
0.5 mM24 hBSANo↔ (≈81.2 ± 5%) SEM↔ (≈80.0 ± 5%) SEM ↔ (≈78.2 ± 5%) SEMEo et al., 2022 [122]
0.5 mM24 hBSA50 nM × 15 min↔ (≈68.4 ± 5%) SEM↓ (≈45.2 ± 5%) SEM ↓ (≈64.7 ± 5%) SEMEo et al., 2022 [122]
0.5 mM24 hBSANo ↔ Thr308 (≈138.4 ± 5%) SEM Rios-Morales et al., 2022 [123]
0.5 mM24 hBSANo ↔ Ser473(≈70.0 ± 5%) SEM Rios-Morales et al., 2022 [123]
0.5 mM24 hBSA100 nM × 20 min ↓ (≈71.4 ± 5%) SEM Rios-Morales et al., 2022 [123]
0.5 mM24 hBSANo ↔ (≈85.7 ± 5%) SEM Li et al., 2021 [124]
0.5 mM24 hBSA100 nM × 20 min ↓ (≈38.8 ± 5%) SEM Li et al., 2021 [124]
0.5 mM24 hBSA7 nM × 15 min ↓ (≈21.9 ± 5%) Rodrigues et al., 2021 [125]
0.5 mM24 hBSA200 nM × 20 min↓ (≈51.0 ± 5%)↓ (≈67.9 ± 5%) Munoz et al., 2021 [126]
0.5 mM24 hBSANo ↓ (≈42.3 ± 5%)↓ (≈63.3 ± 5%)Guo 2021 et al. [127]
0.5 mM24 hBSA10 nM × 15 min↓ (≈80.0 ± 5%)↓ (≈69.3 ± 5%) Luo et al., 2020 [128]
0.5 mM24 hBSA100 nM × unknown ↓ (≈65.3 ± 5%) ↓ (≈54.0 ± 5%)Chen et al., 2019 [129]
0.5 mM24 hBSANo ↓ (≈63.1 ± 5%) Guo et al., 2020 [130]
0.5 mM24 hBSA1 µM × 60 min ↓ (≈75.4 ± 5%) Guo et al., 2020 [130]
0.5 mM24 hBSAunknown ↓ (≈47.3 ± 5%) Liu et al., 2019 [131]
0.5 mM24 hBSA100 nM × unknown↓ (≈52.8 ± 5%)↓ (≈30.1 ± 5%) Bakhtiyari et al., 2019 [132]
0.5 mM24 hBSANo↓ (≈61.3 ± 5%) ↓ (≈55.0 ± 5%) Zhang et al., 2018 [17]
0.5 mM24 hBSA10 nM × 30 min ↓ (≈51.2 ± 5%) Huang et al., 2017 [133]
0.5 mM24 hBSA100 nM × 10 min ↔ VC Dziewulska et al., 2012 [134]
0.5 mM24 hBSA100 nM × 10 min ↓ (≈17.9 ± 5%) Dziewulska et al., 2012 [134]
0.5 mM18 h + 9 hNo10 nM × 20 min ↓ (≈0.00 ± 5%) Aswad et al., 2014 [113]
0.5 mM18 h + 9 hBSA10 nM × 20 min ↓ (≈25.0 ± 5%) Aswad et al., 2014 [113]
0.5 mM48 hBSA100 nM × 30 min ↓ (≈45.4 ± 5%) SEM ↓ (≈55.5 ± 5%)Yoon et al., 2021 [135]
NOTES: * indicates aspects of results were repeated with separate experiment within the same report using similar treatment conditions. NR indicates detail was not reported. VC indicates visual confirmation was used and statistical comparisons were not made for relevant groups or only used single image densitometry. The addition sign (+) following a treatment duration indicates a recovery time following palmitate treatment. Abbreviations: bovine serum albumin (BSA) and ethanol (EtOH). ↓: indicates a reported decrease in the target versus control; ↔: indicates no difference reported in the target versus control; ↑: indicates a reported increase in the target versus control.
Table 3. Findings from systematic search results on the effect of far greater than pharmacokinetically attainable (proof-of-concept) levels of palmitate treatment at various concentrations for various durations on common indicators of insulin sensitivity.
Table 3. Findings from systematic search results on the effect of far greater than pharmacokinetically attainable (proof-of-concept) levels of palmitate treatment at various concentrations for various durations on common indicators of insulin sensitivity.
Palmitate ConcentrationDurationVehicleInsulin StimulationInsulin Receptor Substrate
(pIRS)		Protein Kinase B
(pAkt)		Glucose Transporter 4
(GLUT4)		Glucose UptakeReference
0.6 mM24 hBSANo ↔ (≈75.4 ± 5%) SEM Lee et al., 2022 [136]
0.6 mM24 hBSA100 nM × 15 min ↓ (≈0.00 ± 5%) ↓ (≈62.5 ± 5%)Lee et al., 2022 [136]
0.6 mM24 hBSA100 nM × 15 min ↓ VC↓ (≈21.2 ± 5%) SEM↓ (≈73.4 ± 5%) SEMYang et al., 2013 [47]
0.6 mM24 hBSANo ↓ (≈21.7 ± 5%) Abe et al., 2016 [137]
0.6 mM24 hBSA100 nM × 60 min ↓ (≈37.6 ± 5%) Abe et al., 2016 [137]
0.6 mM24 hBSANo ↓ (≈30.7 ± 5%) SEM Yang et al., 2012 [50]
0.6 mM24 hBSA100 nM × 30 min ↓ (≈29.4 ± 5%) SEM Yang et al., 2012 [50]
0.6 mM 48 h BSAunknown ↓ (≈24.4 ± 5%) Tang et al., 2018 [138]
0.7 mM18 hBSANo ↔ (≈100.0 ± 5%) Rieusset et al., 2012 [139]
0.7 mM18 hBSA10 nM × 20 min ↓ (≈29.2 ± 5%) Rieusset et al., 2012 [139]
0.75 mM1 hBSA100 nM × 10 min ↓ VC Hage Hassan et al., 2012 [60]
0.75 mM2 hBSANo↑ (≈266.6 ± 5%)↔ (≈100.0 ± 5%) ↓ (≈71.7 ± 5%)Schmitz-Peiffer et al., 1999 [4]
0.75 mM2 hBSA100 nM × 10 min↔ (≈93.7 ± 5%)↓ (≈58.9 ± 5%) ↓ (≈77.1 ± 5%)Schmitz-Peiffer et al., 1999 [4]
0.75 mM2 hBSA100 nM × 10 min ↓ VC Hage Hassan et al., 2012 [60]
0.75 mM4 hBSA100 nM × 10 min ↓ VC Hage Hassan et al., 2012 [60]
0.75 mM5 hBSANo↑ (≈268.5 ± 5%)↔ VC Deng et al., 2012 [140]
0.75 mM5 hBSA100 nM × 10 min↓ (≈58.1 ± 5%)↔ VC Deng et al., 2012 [140]
0.75 mM6 hBSA10 nM × 10 min ↔ (≈85.7 ± 5%) De Hart et al., 2023 [141]
0.75 mM6 hBSA10 nM × 10 min ↓ VC Wang et al., 2009 [142]
0.75 mM8 hBSA100 nM × 60 min ↓(≈54.5 ± 5%)↓(≈45.1 ± 5%)Samra et al., 2024 [143]
0.75 mM12 hBSA10 nM × 10 min ↔ (≈71.4 ± 5%) De Hart et al., 2023 [141]
0.75 mM12 hBSA10 nM × 10 min ↓ VC Wang et al., 2009 [142]
0.75 mM16 hEtOHNo ↔ (≈92.5 ± 5%)Parvaneh et al., 2010 [27]
0.75 mM16 hEtOH100 nM × 30 min ↓ (≈71.6 ± 5%)Parvaneh et al., 2010 [27]
0.75 mM 16 h BSANo ↓ (≈43.8 ± 5%)↓ (≈32.5 ± 5%) ↓ (≈61.7 ± 5%) Yoon et al., 2018 [144]
0.75 mM 16 h BSA1 µM × unknown ↓ (≈44.6 ± 5%) ↓ (≈74.5 ± 5%) Yoon et al., 2018 [144]
0.75 mM 16 h BSA100 nM × 15 min ↓ (≈80.8 ± 5%) SEM↓ (≈67.6 ± 5%) SEM Hsieh et al., 2014 [145]
0.75 mM 16 h BSA100 nM × 10 min ↓ VC Bandet et al., 2023 [146]
0.75 mM16 hBSA100 nM × 30 min ↓ (≈56.8 ± 5%)↓ (≈62.0 ± 5%) Lin et al., 2017 [147]
0.75 mM16 hBSA100 nM × 15 min ↓ (≈53.2 ± 5%) ↓ (≈8.6 ± 5%)Feraco et al., 2023 [148]
0.75 mM16 hBSA1 µM × 10 min ↓ (≈6.3 ± 5%) ↓ (≈47.9 ± 5%)Mazibuko-Mbeje et al., 2022 [149]
0.75 mM16 hBSA100 nM × 10 min↓ (≈60.6 ± 5%)↓ (≈44.4 ± 5%)↓ (≈80.0 ± 5%) Chen et al., 2021 [150]
0.75 mM16 hBSA100 nM × unknown ↓ (≈70.8 ± 5%)Zhang et al., 2021 [151]
0.75 mM16 hBSANo ↔ (≈70.0 ± 5%) SEM Bitsi, 2020 [152]
0.75 mM16 hBSA100 nM × 30 min ↓ (≈55.1 ± 5%) SEM Bitsi, 2020 [152]
0.75 mM16 hBSA100 nM × 15 min ↓ (≈47.8 ± 5%) SEM de Mendonça et al., 2020 [153]
0.75 mM16 hBSANo ↔ (≈112.1 ± 5%) SEMHuang et al., 2019 [154]
0.75 mM16 hBSA10 nM × 30 min ↓ Thr308 (≈57.5 ± 5%) SEM Huang et al., 2019 [154]
0.75 mM16 hBSA10 nM × 30 min ↓ Ser473 (≈44.1 ± 5%) SEM ↓ (≈95.3 ± 5%) SEMHuang et al., 2019 [154]
0.75 mM16 hBSANo ↓ (≈6.3 ± 5%) Ayeleso et al., 2018 [155]
0.75 mM16 hBSA100 nM × 30 min↓ (≈59.0 ± 5%)↔ (≈70.8 ± 5%) Xu et al., 2017 [156]
0.75 mM16 hUnconjugated100 nM × 30 min ↓ (≈92.0 ± 5%) SEMLee et al., 2017 [58]
0.75 mM16 hBSA100 nM × 30 min ↓ (≈31.8 ± 5%) SEMLee et al., 2017 [58]
0.75 mM16 hBSAYes, unknown conditions↓ (≈32.0 ± 5%)↓ (≈36.0 ± 5%) ↓ (≈56.5 ± 5%)Zhou et al., 2017 [157]
0.75 mM16 hBSA100 nM × 30 min↓ (≈26.3 ± 5%)↓ Thr308 (≈54.0 ± 5%)↓ (≈13.7 ± 5%)↓ (≈71.4 ± 5%)Zhu et al. [158]
0.75 mM16 hBSA100 nM × 30 min ↓ Ser473 (≈64.8 ± 5%) Zhu et al. [158]
0.75 mM16 hBSANo ↔ (≈93.3 ± 5%)Haghani et al., 2015 [159]
0.75 mM16 hBSA100 nM × 30 min↓ (≈58.9 ± 5%)↓ (≈38.6 ± 5%) ↓ (≈62.7 ± 5%)Haghani et al., 2015 [159]
0.75 mM16 hBSANo ↔ (≈89.6 ± 5%)Li et al. [160]
0.75 mM16 hBSA100 nM × 30 min↓ (≈40.4 ± 5%)↓ (≈36.9 ± 5%)↓ VC↓ (≈70.2 ± 5%)Li et al. [160]
0.75 mM16 hBSANo ↓ (≈40.0 ± 5%)↓ (≈42.0 ± 5%)↓ (≈59.5 ± 5%)Chen et al., 2015 [161]
0.75 mM16 hBSA10 nM × 15 min ↓ (≈55.3 ± 5%)↓ (≈43.4 ± 5%)↓ (≈30.5 ± 5%)Chen et al., 2015 [161]
0.75 mM16 hBSA100 nM × 10 min ↓ (≈40.0 ± 5%) Mahfouz et al., 2014 [162]
0.75 mM16 hBSANo ↓ VC Fabre et al., 2014 [163]
0.75 mM16 hBSA1 nM × 10 min ↓ VC Fabre et al., 2014 [163]
0.75 mM16 hBSANo ↓ (≈33.3 ± 5%)↓ (≈33.3 ± 5%)↓ (≈33.3 ± 5%)Mazibuko et al., 2013 [164]
0.75 mM16 hBSA1 µM × 15 min ↓ (≈60.7 ± 5%)↓ (≈15.9 ± 5%)↓ (≈23.0 ± 5%)Mazibuko et al., 2013 [164]
0.75 mM16 hBSANo ↔ (≈93.7 ± 5%)Zhang et al., 2010 [61]
0.75 mM16 hBSA100 nM × 20 min ↓ (≈72.0 ± 5%)Zhang et al., 2010 [61]
0.75 mM *16 hBSA100 nM × 20 min↑ (≈266.6 ± 5%)↓ (≈43.5 ± 5%)↑ (≈127.7 ± 5%)↓ (≈73.7 ± 5%)Zhang et al., 2010 [61]
0.75 mM16 hEtOHNo ↓ (≈50.0 ± 5%) Peterson et al., 2008 [165]
0.75 mM16 hBSANo ↓ VC Chavez et al., 2003 [166]
0.75 mM16 hBSA100 nM × 10 min ↓ VC Chavez et al., 2003 [166]
0.75 mM16 hBSA100 nM × 10 min ↓ VC Chavez et al., 2005 [11]
0.75 mM *16 hBSA100 nM × 10 min ↓ VC Chavez et al., 2005 [11]
0.75 mM16 hBSA100 nM × 10 min↓ (≈20.0 ± 5%)↓ VC Jove et al., 2006 [167]
0.75 mM16 hBSANo↓ VC↓ VC Deng et al., 2012 [140]
0.75 mM16 hBSA100 nM × 10 min↓ VC↓ VC ↓ (≈85.4 ± 5%)Deng et al., 2012 [140]
0.75 mM16 hBSA100 nM × 10 min ↓ VC Hage Hassan et al., 2012 [60]
0.75 mM *16 hBSA100 nM × 10 min ↓ (≈48. ± 5%) Hage Hassan et al., 2012 [60]
0.75 mM18 hBSAUnknown ↓ (≈77.1 ± 5%) Aguer et al., 2014 [168]
0.75 mM *18 hBSA10 nM × 10 min ↓ (≈11.1 ± 5%) Wang et al., 2009 [142]
0.75 mM18 hBSA10 nM × 10 min ↓ (≈32.1 ± 5%) Wang et al., 2009 [142]
0.75 mM18 hBSANo ↔ (≈100.0 ± 5%)↔ (≈100.0 ± 5%) Li et al., 2013 [169]
0.75 mM18 hBSA100 nM × 30 min ↓ (≈16.6 ± 5%)↓ (≈21.6 ± 5%) Li et al., 2013 [169]
0.75 mM19 hBSA10 nM × 10 min ↓ VC Blackburn et al., 2020 [28]
0.75 mM19 hBSA100 nM × 10 min ↓ VC Blackburn et al., 2020 [28]
0.75 mM24 hBSA100 nM × 15 min ↓ VC↓ VC↓ (≈60.6 ± 5%)Chen et al., 2016 [170]
0.75 mM24 hBSA100 nM × 30 min ↑ (≈164.1 ± 5%) ↓ (≈50.7 ± 5%) Chen et al., 2020 [171]
0.75 mM24 hBSANo ↓ (≈63.1 ± 5%) Zhang et al., 2024 [83]
0.75 mM24 hBSA100 nM × 30 min ↓ (≈47.3 ± 5%)Zhang et al., 2024 [83]
0.75 mM24 hBSA100 nM × 10 min ↓ (≈70.0 ± 5%)Swargiary et al., 2024 [172]
0.75 mM24 hBSA10 nM × 10 min ↓ (≈56.5 ± 5%) De Hart et al., 2023 [141]
0.75 mM24 hBSANo ↔ (≈89.4 ± 5%)Zhang et al., 2021 [173]
0.75 mM24 hBSA30 mU/mL × 60 min↓ (≈18.1 ± 5%)↓ (≈17.6 ± 5%) ↓ (≈66.6 ± 5%)Zhang et al., 2021 [173]
0.75 mM24 hBSANo ↓ (≈53.1 ± 5%)↓ (≈67.2 ± 5%)Wang et al., 2021 [174]
0.75 mM24 hBSA100 nM × 30 min ↓ (≈52.0 ± 5%)↓ (≈61.1 ± 5%)Wang et al., 2021 [174]
0.75 mM24 hBSANo↓ VC↓ VC Han et al., 2020 [175]
0.75 mM24 hBSAYes, unknown↓ VC↓ VC Han et al., 2020 [175]
0.75 mM24 hBSA100 nM × unknown ↓ (≈14.0 ± 5%)Chen et al., 2019 [129]
0.75 mM24 hBSANo↓ (≈40.9 ± 5%) ↓ (≈51.7 ± 5%) Zhang et al., 2018 [17]
0.75 mM24 hBSANo ↓ (≈28.5 ± 5%)Bakar et al., 2017 [176]
0.75 mM24 hBSA100 nM × 30 min ↓ (≈38.2 ± 5%) ↓ (≈20.0 ± 5%)Bakar et al., 2017 [176]
0.75 mM24 hBSANo↑ VC↓ VC ↓ (≈64.8 ± 5%)Kwak et al., 2017 [177]
0.75 mM24 hBSA1 μg/mL × 30 min↑ VC↓ VC ↓ (≈57.1 ± 5%)Kwak et al., 2017 [177]
0.75 mM24 hBSA10 nM × 30 min ↓ (≈25.6 ± 5%) Huang et al., 2017 [133]
0.75 mM24 hBSANo↔ (≈236.0 ± 5%)↔ (≈50.0 ± 5%) ↔ (≈47.8 ± 5%)Li et al., 2017 [178]
0.75 mM24 hBSA100 nM × 30 min↓ (≈256.0 ± 5%)↓ (≈45.7 ± 5%) ↓ (≈40.4 ± 5%)Li et al., 2017 [178]
0.75 mM24 hBSANo↓ (≈21.4 ± 5%)↓ (≈11.1 ± 5%)↔ (≈92.3 ± 5%)↔ (≈78.5 ± 5%)Kwak et al., 2016 [179]
0.75 mM24 hBSA1 μg/mL × 30 min↓ (≈21.5 ± 5%)↓ (≈39.2 ± 5%)↓ (≈50.0 ± 5%)↓ (≈61.3 ± 5%)Kwak et al., 2016 [179]
0.75 mM24 hBSANo ↔ (≈90.0 ± 5%)Meshkani et al., 2014 [180]
0.75 mM24 hBSA100 nM × 30 min ↓ (≈62.9 ± 5%) ↓ (≈70.5 ± 5%)Meshkani et al., 2014 [180]
0.75 mM24 hBSANo ↓ VC Dymkowska et al., 2014 [181]
0.75 mM24 hBSA10 nM × 20 min ↓ (≈51.7 ± 5%) ↓ (≈83.0 ± 5%)Dymkowska et al., 2014 [181]
0.75 mM24 hBSA10 nM × 10 min ↓ (≈9.7 ± 5%) Wang et al., 2009 [142]
0.75 mM24 hBSA10 nM × 10 min ↓ (≈16.3 ± 5%) Senn et al., 2006 [182]
0.75 mM48 hBSANo ↓ (≈39.1 ± 5%) Yu et al., 2024 [183]
0.8 mM18 hBSANo ↔ (≈90.9 ± 5%) D’Souza et al., 2018 [184]
0.8 mM18 hBSA20 nM × 15 min ↓ (≈70.2 ± 5%) D’Souza et al., 2018 [184]
0.8 mM18 hBSA200 nM × 30 min↑ (≈271.4 ± 5%)↑ (≈131.8 ± 5%) Lui et al., 2012 [185]
1 mM 16 h BSANo ↓ VC ↑ (≈207.4 ± 5%) SEMKadotani et al., 2008 [186]
1 mM 16 h BSA2 nM × 30 min ↓ VC Kadotani et al., 2008 [186]
1 mM 16 h BSA10 nM × 30 min ↓ VC Kadotani et al., 2008 [186]
1 mM 16 h BSA100 nM × 30 min ↓ VC ↓ (≈78.2 ± 5%) SEMKadotani et al., 2008 [186]
1 mM16 hUnconjugated100 nM × 30 min ↓ (≈84.0 ± 5%) SEMLee et al., 2017 [58]
1 mM16 hBSA100 nM × 30 min ↓ (≈30.6 ± 5%) SEMLee et al., 2017 [58]
1 mM16 hBSANo ↓ (≈76.1 ± 5%) Zhou et al., 2007 [59]
1 mM16 hBSANo↑ (≈191.8 ± 5%)↔ (≈150.0 ± 5%) ↓ (≈75.8 ± 5%)Ragheb et al., 2009 [187]
1 mM16 hBSA100 nM × 10 min↑ (≈159.0 ± 5%)↓ (≈72.2 ± 5%) ↓ (≈60.0 ± 5%)Ragheb et al., 2009 [187]
1 mM16 hBSA100 nM × 30 min ↓ VC Tsuchiya et al., 2010 [188]
1 mM16 hBSA100 nM × 10 min ↓ (≈42.8 ± 5%) Kusudo et al., 2011 [189]
1 mM16 hBSANo ↔ (≈90.6 ± 5%)Zhang et al., 2010 [61]
1 mM16 hBSA100 nM × 20 min ↓ (≈72.0 ± 5%)Zhang et al., 2010 [61]
1 mM17 hBSA100 nM × 10 min ↓ Thr308 (≈16.6 ± 5%) Pierre et al., 2016 [190]
1 mM17 hBSA100 nM × 10 min ↓ Ser473 (≈29.6 ± 5%) Pierre et al., 2016 [190]
1 mM 24 h BSANo ↔ (≈103.2 ± 5%)↔ (≈119.2 ± 5%)Vong et al., 2025 [191]
1 mM 24 h BSA500 nM × unknown ↓ (≈80.8 ± 5%)↓ (≈81.6 ± 5%)Vong et al., 2025 [191]
1 mM 24 h BSA100 nM × 30 min ↓ (≈37.9 ± 5%)Kim et al., 2024 [192]
1 mM24 hBSANo ↓ (≈24.5 ± 5%)↓ (≈40.0 ± 5%)Xiang et al., 2023 [193]
1 mM24 hBSA100 nM × 30 min ↓ Cytosolic (≈78.1 ± 5%) Kim et al., 2020 [194]
1 mM24 hBSA100 nM × 30 min↑ (≈147.2 ± 5%)↓ (≈36.6 ± 5%)↓ Membranous (≈42.4 ± 5%)↓ (≈53.2 ± 5%)Sun et al., 2020 [195]
1 mM 48 h BSA17 nM × 15 min ↓ (≈24.5 ± 5%)↓ (≈20.8 ± 5%) Zhou et al., 2008 [196]
1 mM48 hBSA100 nM × 15 min↓ (≈40.7 ± 5%)↓ (≈68.6 ± 5%)↓ (≈42.6 ± 5%) Sun et al., 2020 [195]
1.2 mM 16 h BSA 100 nM × 15 min ↓ (≈72.3 ± 5%) SEM↓ (≈55.8 ± 5%) SEM Hsieh et al., 2014 [145]
NOTES: * indicates aspects of results were repeated with separate experiment within the same report using similar treatment conditions. NR indicates detail was not reported. VC indicates visual confirmation was used and statistical comparisons were not made for relevant groups or only used single image densitometry. Abbreviations: bovine serum albumin (BSA). ↓: indicates a reported decrease in the target versus control; ↔: indicates no difference reported in the target versus control; ↑: indicates a reported increase in the target versus control.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Zimmerman, J.M.; Klein, A.J.; Travis, K.B.; Vaughan, R.A. A Systematic Review of Palmitate-Mediated Insulin Resistance in C2C12 Myotubes. Nutrients 2025, 17, 3619. https://doi.org/10.3390/nu17223619

AMA Style

Zimmerman JM, Klein AJ, Travis KB, Vaughan RA. A Systematic Review of Palmitate-Mediated Insulin Resistance in C2C12 Myotubes. Nutrients. 2025; 17(22):3619. https://doi.org/10.3390/nu17223619

Chicago/Turabian Style

Zimmerman, John M., Alexa J. Klein, Kipton B. Travis, and Roger A. Vaughan. 2025. "A Systematic Review of Palmitate-Mediated Insulin Resistance in C2C12 Myotubes" Nutrients 17, no. 22: 3619. https://doi.org/10.3390/nu17223619

APA Style

Zimmerman, J. M., Klein, A. J., Travis, K. B., & Vaughan, R. A. (2025). A Systematic Review of Palmitate-Mediated Insulin Resistance in C2C12 Myotubes. Nutrients, 17(22), 3619. https://doi.org/10.3390/nu17223619

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop